WO2005040220A1 - Multispecific deimmunized cd3-binders - Google Patents
Multispecific deimmunized cd3-binders Download PDFInfo
- Publication number
- WO2005040220A1 WO2005040220A1 PCT/EP2004/011646 EP2004011646W WO2005040220A1 WO 2005040220 A1 WO2005040220 A1 WO 2005040220A1 EP 2004011646 W EP2004011646 W EP 2004011646W WO 2005040220 A1 WO2005040220 A1 WO 2005040220A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- acid sequence
- nucleic acid
- specific binding
- construct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
Definitions
- the present invention relates to a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmacutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
- Human CD3 denotes an antigen which is expressed on T cells as part of the multimolecular T cell complex and which consists of three different chains: CD3- ⁇ , CD3- ⁇ and CD3- ⁇ .
- Clustering of CD3 on T cells, e.g, by immobilized anti-CD3 antibodies leads to T cell activation similar to the engagement of the T cell receptor but independent of its clone-typical specificity; see WO 99/54440 or Hoffman (1985) J. Immunol. 135:5-8.
- Antibodies which specifically recognize CD3 antigen are described in the prior art, e.g. in Traunecker, EMBO J 10 (1991), 3655-9 and Kipriyanov, Int. J. Cancer 77 (1998), 763-772. Lately, antibodies directed against CD3 have been proposed in the treatment of a variety of diseases. These antibodies or antibody constructs act as either T-cell depleting agents or as mitogenic agents, as disclosed in EP 1 025 854. Human/rodent hybrid antibodies which specifically bind to the human CD3 antigen complex are disclosed in WO 00/05268 and are proposed as immunosuppressive agents, for example for the treatment of rejection episodes following the transplantation of the renal, septic and cardiac allografts.
- WO 03/04648 discloses a bispecific antibody directed to CD3 and to an ovarian cancer antigen. Furthermore, Kufer (1997) Cancer Immunol Immunother 45:193-7 relates to a bispecific antibody specific for CD3 and EpCAM for the therapy of minimal residual cancer.
- CRS cytokine release syndrome
- CRS symptoms range from frequently reported mild "flu-like” symptoms to less frequently reported severe "shock-like” reactions (which may include cardiovascular and central nervous system manifestations).
- Symptoms include, inter alia, headache, tremor, nausea/vomiting, diarrhoea, abdominal pain, malaise and muscle/joint aches and pains, generalized weakness, cardiorespiratory events as well as neuro- psychiatric events. Severe pulmonary oedema has occurred in patients with fluid overload and in those who appeared not to have a fluid overload.
- HAMAs human anti-mouse antibodies
- Fc murine constant
- V murine variable
- humanization entails substitutions of non-human antibody sequences for corresponding human sequences, as for example is the case with CDR-grafting.
- deimmunization Another approach to reducing the immunogenicity of such antibodies is by deimmunization, as for example described in WO 00/34317, WO 98/52976, WO 02/079415, WO 02/012899 and WO 02/069232.
- deimmunization entails carrying out substitutions of amino acids within potential T cell epitopes. In this way, the likelihood that a given sequence will give rise to T cell epitopes upon intracellular protein processing is reduced.
- WO 92/10755 describes an approach in which antigenic determinants on proteins are engineered. Particularly, proteins are epitope mapped and their amino acid sequence is changed through genetic engineering.
- humanized antibodies often exhibit a decreased binding affinity with respect to their target as compared to their non-humanized parent antibodies and also often are still somewhat immunogenic in a human host.
- the technical problem of the present invention was the provision of means and methods for the treatment of and/or the amelioration of tumorous diseases, proliferative disorders as well as B-cell related diseases by induction of T cell mediated immune response.
- the above-mentioned means and methods should overcome the recited disadvantages of known antibody-based therapies.
- the present invention relates to a cytotoxically active CD3 specific binding construct
- a first domain specifically binding to human CD3 and an Ig-derived second binding domain
- said first domain is deimmunized and comprises a CDR-H1 region, a CDR- H2 region and a CDR-H3 region, said CDR-H3 region comprising an amino acid sequence as depicted in SEQ ID NO.: 96, 108, 119, 120, 121 , 122, 123, 124, 125, 126, or 127
- said first domain further comprises in its framework H1 the sequence VKK (Val-Lys-Lys) and wherein the transition sequence between framework H1 and CDR- H1 region comprises the sequence Ala-Ser-Gly-Tyr-Thr-Phe (ASGYTF; SEQ ID NO.: 233).
- a desired, inventive CD3- specific binding construct is characterized as comprising at least two binding specificities whereby a second binding specificity is Ig-derived.
- said desired constructs are characterized by the specific amino acid sequences shown herein above. As documented in the appended examples the constructs as provided herein still retain bioactivity in their modified/deimmunized form.
- the examples also document that not all deimmunizations, determined by methods known in the art (WO 92/10755, WO 00/34317, WO 98/52976, WO 02/079415 or WO 02/012899), lead to bioactive molecules; see in particular the examples 2 and 5.
- the term "cytotoxically active CD3 binding construct” as used herein relates to a CD3 specific construct capable of binding to human CD3 complex expressed on T cells and capable of inducing elimination/lysis of target cells.
- CD3 specific binders of the CD3/CD3 complex leads to activation of T cells as known in the art; see WO 99/54440.
- an inventive construct has to be able to eliminate/lyse target cells in vivo and/or in vitro.
- Corresponding target cells comprise cells expressing a surface molecule, which is recognized by the second Ig-derived binding domain of the inventive constructs.
- Such surface molecules are characterized herein below. Cytotoxicity can be detected by methods known in the art and methods as illustrated herein below and in the appended examples. Accordingly, such methods comprise, inter alia, physiological in vitro assays.
- Such physiological assays may monitor cell death, for example by loss of cell membrane integrity (e.g. FACS based propidium Iodide assay, trypan Blue influx assay, photometric enzyme release assays (LDH), radiometric 51 Cr release assay, fluorometric Europium release and CalceinAM release assays).
- Further assays comprise monitoring of cell viability, for example by photometric MTT, XTT, WST-1 and alamarBlue assays, radiometric 3 H-Thd incorporation assay, clonogenic assay measuring cell division activity, and fluorometric Rhodamine 123 assay measuring mitochondrial transmembrane gradient.
- apoptosis may be monitored for example by FACS-based phosphatidylserin exposure assay, ELISA-based TUNEL test, caspase activity assay (photometric, fluorometric or ELISA-based) or analysing changed cell morphology (shrinking, membrane blebbing). It is preferred that cytotoxic activity is analysed by FACS-based measurements of release of fluorescence-based dyes.
- fluorescence labelled cells which carry a molecule which binds to the second domain of the cytotoxically active bispecific CD3 binding construct of the invention (preferably, NALM-6 cells for CD19 and Kato cells for the EpCAM antigen) are incubated with isolated PBMCs of random donors or with a standardized T-cell line in the presence of the cytotoxically active bispecific CD3 binding construct of the invention. After incubation, the release of the dye from the fluorescent target cells into the supernatant is determined by a spectrofluorimeter.
- a cytotoxically active deimmunized bispecific CD3 binding construct of the present invention is characterized by comparing values obtained by measuring the bioactivity of a similar construct which is not deimmunized or has no specificity to the target cells.
- binding to/interacting with defines a binding/interaction of at least two "antigen-interaction-sites" with each other.
- antigen-interaction-site defines, in accordance with the present invention, a motif of a polypeptide which shows the capacity of specific interaction with a specific antigen or a specific group of antigens. Said binding/interaction is also understood to define a "specific recognition".
- the term "specifically recognizing” means in accordance with this invention that the antibody molecule is capable of specifically interacting with and/or binding to at least two amino acids of each of the human target molecules as defined herein.
- Antibodies can recognize, interact and/or bind to different epitopes on the same target molecule. Said term relates to the specificity of the antibody molecule, i.e. to its ability to discriminate between the specific regions of the human target molecule as defined herein.
- the specific interaction of the antigen-interaction-site with its specific antigen may result in an initiation of a signal, e.g. due to the induction of a change of the conformation of the antigen, an oligomerization of the antigen, etc.
- a specific motif in the amino acid sequence of the antigen-interaction-site and the antigen bind to each other as a result of their primary, secondary or tertiary structure as well as the result of secondary modifications of said structure.
- the term "specific interaction" as used in accordance with the present invention means that the CD3 specific binding construct of the invention does not or essentially does not cross-react with (poly)peptides of similar structures. Accordingly, the construct of the invention specifically binds to/interacts with human CD3 and is capable, due to its second, Ig-derived domain to interact with specific, selected other compounds, antigens, cell surface markers, tumor markers, etc. Specific examples of such molecules against which said second, Ig-derived domain is directed are given herein below.
- Cross-reactivity of a panel of constructs under investigation may be tested, for example, by assessing binding of said panel of bispecific single chain constructs under conventional conditions (see, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988 and Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1999) to the (poly)peptide of interest as well as to a number of more or less (structurally and/or functionally) closely related (poly)peptides. Only those constructs (i.e.
- antibodies that bind to the (poly)peptide/protein of interest but do not or do not essentially bind to any of the other (poly)peptides which are preferably expressed by the same tissue as the (poly)peptide of interest, e.g. by the cells of the heart tissue, are considered specific for the (poly)peptide/protein of interest and selected for further studies in accordance with the method provided herein and illustrated in the appended examples.
- These methods may comprise, inter alia, binding studies, blocking and competition studies with structurally and/or functionally closely related molecules.
- binding studies also comprise FACS analysis, surface plasmon resonance (SPR, e.g.
- examples for the specific interaction of an antigen- interaction-site with a specific antigen may comprise the specificity of a ligand for its receptor. Said definition particularly comprises the interaction of ligands which induce a signal upon binding to its specific receptor. Examples for corresponding ligands comprise cytokines which interact/bind with/to its specific cytokine-receptors.
- an antigen-interaction-site to antigens such as antigens of the selectin family, integrins and of the family of growth factors like EGF.
- Another example for said interaction is the interaction of an antigenic determinant (epitope) with the antigenic binding site of an antibody.
- binding to/interacting with relates not only to a linear epitope but may also relate to a conformational epitope, a structural epitope or a discontinuous epitope consisting of two regions of the human target molecules or parts thereof.
- a conformational epitope is defined by two or more discrete amino acid sequences separated in the primary sequence which come together on the surface of the molecule when the polypeptide folds to the native protein (Sela, (1969) Science 166, 1365 and Laver, (1990) Cell 61, 553-6).
- discontinuous epitope means in context of the invention non-linear epitopes that are assembled from residues from distant portions of the polypeptide chain. These residues come together on the surface when the polypeptide chain folds into a three-dimensional structure to constitute a conformational/structural epitope.
- the constructs of the present invention are also envisaged to specifically bind to/interact with a conformational/structural epitope(s) composed of and/or comprising the two regions of the human CD3 complex described herein or parts thereof as disclosed herein below.
- Ig-derived second binding domain relates to an "immunoglobulin-derived domain” , specifically to an antibody or fragments thereof, to single chain antibodies, to synthetic antibodies, to antibody fragments, such as Fab, a F(ab 2 )', Fv or scFv fragments etc, or a chemically modified derivative of any of these. These antibodies molecules may be derived from different species or may be of chimeric origin. Most preferably (as documented herein below), said Ig-derived second domain comprised in the CD3 specific binding construct of the invention is a scFv.
- Antibodies, antibody constructs, antibody fragments, antibody derivatives (all being Ig-derived) to be employed in accordance with the invention or their corresponding immunoglobulin chain(s) can be further modified using conventional techniques known in the art, for example, by using amino acid deletion(s), insertion(s), substitution(s), addition(s), and/or recombination(s) and/or any other modification(s) known in the art either alone or in combination. Methods for introducing such modifications in the DNA sequence underlying the amino acid sequence of an immunoglobulin chain are well known to the person skilled in the art; see, e.g., Sambrook (1989), loc. cit.
- the term "Ig-derived domain" particularly relates to (poly)peptide constructs comprising at least one CDR.
- Fragments or derivatives of the recited Ig-derived domains define (poly)peptides which are parts of the above antibody molecules and/or which are modified by chemical/biochemical or molecular biological methods.
- Corresponding methods are known in the art and described inter alia in laboratory manuals (see Sambrook et al.; Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press, 2nd edition 1989 and 3rd edition 2001 ; Gerhardt et al.; Methods for General and Molecular Bacteriology; ASM Press, ' 1994; Lefkovits; Immunology Methods Manual: The Comprehensive Sourcebook of Techniques; Academic Press, 1997; Golemis; Protein-Protein Interactions: A Molecular Cloning Manual; Cold Spring Harbor Laboratory Press, 2002).
- the term "deimmunized” as used herein relates to the above-identified first domain of the inventive CD3 binding construct, wherein said first domain is modified compared to an original wildtype construct by rendering said wildtype construct non- immunogenic or less immunogenic in humans.
- Wildtype constructs according to the invention relate to antibodies or parts thereof (like frameworks and/or CDRs) of non- human origin. Corresponding examples are antibodies or fragments thereof as described in US 4,361 ,549 or WO 99/54440.
- the term “deimmunized” also relates to constructs, which show reduced propensity to generate T cell epitopes.
- reduced propensity to generate T cell epitopes relates to the removal of T-cell epitopes leading to specific T-cell activation. Furthermore, reduced propensity to generate T cell epitopes means substitution of amino acids contributing to the formation of T cell epitopes, i.e. substitution of amino acids, which are essential for formation of a T cell epitope. In other words, reduced propensity to generate T cell epitopes relates to reduced immunogenicity or reduced capacity to induce antigen independent T cell proliferation. In addition, reduced propensity to generate T cell epitopes relates to deimmunisation, which means loss or reduction of potential T cell epitopes of amino acid sequences inducing antigen independent T cell proliferation.
- a CD3 binding region which has reduced propensity to generate T cell epitopes is less or preferably non immunogenic compared to non-deimmunized molecule but which has still retained its capacity to binding to CD3, i,e. a low or non immunogenic antibody construct binding to CD3.
- T cell epitope relates to short peptide sequences which can be released during the degradation of peptides, polypeptides or proteins within cells and subsequently be presented by molecules of the major histocompatibility complex (MHC) in order to trigger the activation of T cells; see inter alia WO 02/066514.
- MHC major histocompatibility complex
- a deimmunized first domain specifically binding to a human CD3 comprises at least the above mentioned CDR-H3 located between framework H3 and H4, wherein said first binding domain shows a reduced propensity to generate T-cell epitopes compared to a non-deimmunized first domain comprising the unchanged wildtype (wt)-CDR-H3 located between framework H3 and H4.
- said deimmunized first domain comprises at least in the transition region of the framework H1 and CDR-H1 the above mentioned sequence motif which provides a reduced propensity to generate T-cell epitopes compared to a non-deimmunized first domain comprising the unchanged wt-H1 transition region of the framework H1 and CDR-H1.
- Reduced propensity to generate T-cell epitopes and/or “deimmunization” may be measured by techniques known in the art.
- deimmunization of proteins may be tested in vitro by a T cell proliferation assay.
- PBMCs from donors representing > 80 % of HLA-DR alleles in the world are screened for proliferation in response to either wildtype or deimmunized peptides.
- cell proliferation is only detected upon loading of the antigen-presenting cells with wildtype peptides.
- one may test deimmunization by expressing HLA-DR tetramers representing all haplotypes.
- tetramers may be tested for peptide binding or loaded with peptides substitute for antigen-presenting cells in proliferation assays.
- binding of e.g. fluorescence-labeled peptides on PBMCs can be measured.
- deimmunization can be proven by determining whether antibodies against the deimmunized molecules have been formed after administration in patients.
- a particular preferred method is a T-cell proliferation assay as, inter alia, shown in appended example 6.
- antibody derived molecules are deimmunized in the framework regions and most of the CDR regions are not modified in order to generate reduced propensity to induce T cell epitope so that the binding affinity of the CDR regions is not affected. Even elimination of one T cell epitope results in reduced immunogenicity.
- the molecule is deimmunized in the CDR2 region of the VL chain, more preferably in the CDR2 region of the VH chain, even more preferably in the CDR1 region of the VL chain, even more preferably in the CDR1 region of the VH chain, more preferably in the framework region (FR) of the VL chain and most preferably in the framework region (FR) of the VH chain.
- CDR as employed herein relates to "complementary determining region", which is well known in the art.
- the CDRs are parts of immunoglobulins and T cell receptors that determine the specificity of said molecules and make contact with specific ligand.
- the CDRs are the most variable part of the molecule and contribute to the diversity of these molecules.
- CDR-H depicts a CDR region of a variable heavy chain and CDR-L relates to a CDR region of a variable light chain.
- H means the variable heavy chain and L means the variable light chain.
- the CDR regions of an Ig-derived region may be determined as described in Kabat (1991).
- CDR-L1 consists of 10-17 amino acid residues, starts approximately at amino acid residue 24 of the full VL region of an Ig-derived sequence and the residue Cys precedes the CDR-L1.
- the residue Trp follows CDR-L1.
- CDR-L2 starts preferably, 16 amino acid residues after CDR-L1 and consists preferably of 7 residues.
- CDR-L3 starts, preferably, 33 amino acid residues after CDR- L2 and consists, preferably, of 7-11 residues.
- CDR-L3 follows, preferably, the residue Cys and, preferably, the residues Phe-Gly-Xaa-Gly follow directly CDR-L3.
- CDR-H 1 consists of, preferably, 10-12 residues and starts, preferably, approximately at residue 26 from the beginning of the VH region.
- the residue Trp follows CDR-H1.
- CDR-H2 starts, preferably, 15 amino acid residues after the end of CDR-H1 and consists, preferably, of 16 to 19 residues.
- residues Lys/Arg- Leu/lle/Val/Phe/Thr/Ala-Thr/Ser/lle/Ala follow CDR-H2.
- CDR-H3 starts 33 amino acid residues after CDR-H2 and has a length of 3-25 amino acid residues.
- CDR-H3 follows the sequence Cys-Xaa-Xaa (preferably Cys-Ala-Arg) and the residues Trp- Gly-Xaa-Gly follow CDR-H3.
- the structure of CDR regions has been described in http://www.bioinf.org.uk/abs/.
- CDR-H 1 and CDR-H2 regions are derived from antibody molecules which are capable of specifically binding to/interacting with human CD3.
- CD3 specific antibody are known in the art and comprise in particular the monoclonal antibodies OKT-3, TR-66 or X35-3, VIT3, BMA030 (BW264/56), CLB- T3/3, CRIS7, YTH12.5, F111-409, CLB-T3.4.2, TR-66, WT32, SPv-T3b, 11 D8, XIII- 141 , XIII-46, XIII-87, 12F6, T3/RW2-8C8, T3/RW2-4B6, OKT3D, M-T301 , SMC2, F101.01 , UCHT-1 or WT-31. All the mentioned anti-CD3 antibodies are human specific and in accordance with this invention it is possible to combine various CDR regions, in particular CDRH regions of the antibodies.
- said CDR-H 1 and CDR-H2 regions of said CD3 specific domain with reduced propensity to generate T cell epitopes are derived from the antibody construct described in WO 99/54440. Even more preferred (and as illustrated in the appended examples) said CDR-H 1 and CDR-H2 regions, as well as the CDR-H3 region, are derived from an antibody/antibody derivative with specificity for the CD3 molecule described by Traunecker (1991), EMBO J. 10, 3655-3659.
- said CDR-H 1 , CDR-H2 and CDR-H3 regions are derived from antibodies/antibody derivatives and the like which are capable of specifically recognizing the human CD3- ⁇ chain in the context of other TCR subunits, e.g. in mouse cells transgenic for human CD3- ⁇ chain. These transgenic mouse cells express human CD3- ⁇ chain in a native or near native conformation.
- a framework region relates to a region in the V domain (VH or VL domain) of immunoglobulins and T-cell receptors that provides a protein scaffold for the hypervariable complementarity determining regions (CDRs) that make contact with the antigen.
- VH or VL domain the V domain of immunoglobulins and T-cell receptors that provides a protein scaffold for the hypervariable complementarity determining regions (CDRs) that make contact with the antigen.
- CDRs hypervariable complementarity determining regions
- Framework 1 encompasses the region from the N-terminus of the V domain until the beginning of CDR1
- framework 2 relates to the region between CDR1 and CDR2
- framework 3 encompasses the region between CDR2 and CDR3
- framework 4 means the region from the end of CDR3 until the C-terminus of the V domain; see, inter alia, Janeway, Immunobiology, Garland Publishing, 2001 , 5th ed.
- the framework regions encompass all the regions outside the CDR regions in VH or VL domains.
- the term "transition sequence between a framework and a CDR region” relates to a direct junction between the framework and CDR region.
- transition sequence between a framework and a CDR region means the sequence directly located N- and C-terminally of the CDR regions or amino acids surrounding CDR regions.
- frameworks may also comprise sequences between different CDR regions.
- the person skilled in the art is readily in a position to deduce from a given sequence the framework regions, the CDRs as well as the corresponding transition sequences; see Kabat (1991) Sequences of Proteins of Immunological Interest, 5th edit., NIH Publication no. 91-3242 U.S. Department of Health and Human Services, Chothia (1987). J. Mol. Biol. 196, 901-917 and Chothia (1989) Nature, 342, 877-883..
- a preferred cytotoxically active CD3 specific binding construct of the invention further comprises in said first domain a framework H3 comprising the sequence Met-Glu- Leu-Ser (MELS; SEQ ID NO.:234). Even more preferred is an inventive construct which comprises in said first domain a framework H3 comprising the sequence lle- Thr-Thr-Asp-Lys (ITTDK; SEQ ID NO.: 235).
- the first domain of the inventive construct specifically binding to/interacting with human CD3 and having a reduced propensity to generate T cell epitopes comprises a CDR-H 1 , CDR-H2 and CDR-H3 regions as defined herein and, in a preferred embodiment, VH-frameworks (frameworks 1 , 2, 3, 4) as defined above, in particular as shown in any one of SEQ ID NOs.: 152 or 153, 156 or 157, 160 or 161 and/or 164 or 165.
- the CD3 specific binding construct of the invention comprises a first domain which specifically binds to human CD3 and comprises a framework region 1 as shown in SEQ ID NO.: 152 or 153, a framework region 2 as shown in SEQ ID NO.: 156 or 157, a framework region 3 as shown in SEQ ID NO.: 160 or 161 and/or a framework region 4 as shown in SEQ ID NO.: 164 or 165.
- the cytotoxically active deimmunized CD3 specific binding construct comprises in its first domain (a) a CDR- H1 as depicted in SEQ ID NO.: 88; and (b) a CDR-H2 as depicted in SEQ ID NO.: 90 or 92.
- the modified CDR-H 1 and CDR-H2 regions lead to a reduced propensity to generate T cell epitopes and are derived from an CD3- ⁇ chain specific antibody.
- said (parental) antibodies should be capable of specifically binding epitopes reflecting the native or near native structure or a conformational epitope of human CD3 presented in context of the TCR complex.
- the CD3 specific binding construct of the invention comprises a VH-region as depicted in SEQ ID NO.:74 or 76.
- SEQ ID NO.:74 shows an illustrative deimmunized variable heavy region and, similarly, SEQ ID NO.:76 shows an illustrative deimmunized variable heavy region.
- the inventive CD3 specific binding construct comprises a CDR-L1 as depicted in SEQ ID NO.: 98 or 100, a CDR-L2 as depicted in SEQ ID NO.:102 and/or a CDR-L3 as depicted in SEQ ID NO.: 104.
- the CD3 specific binding construct of the invention comprises, in a preferred embodiment, a VL region in its CD3-specific portion, wherein said VL region is selected from the group consisting of SEQ ID NO.: 78 , SEQ ID NO.: 80, SEQ ID NO.: 82 and SEQ ID NO.: 112.
- VL1 as characterized in SEQ ID NO.:78, VL2 as characterized in SEQ ID NO.:80 and VL 3 as characterized in SEQ ID NO.:82 relate to full deimmunized VL regions in accordance with this invention, and they may be used in various combinations with the above described VH regions.
- non-deimmunized VL region may be combined, in accordance with the invention, with deimmunized VH regions defined above.
- SEQ ID NOs.: 78, 80, and 82 depict deimmunized VL1 , VL2 and VL3 regions of the CD3 binding part of a construct disclosed in WO 99/54440.
- the CD3 specific binding construct of the invention most preferably, comprises an Ig-derived second domain which is a scFv.
- a deimmunized, bispecific single chain antibody construct is provided with one specificity for human CD3 and a further specificity which is mediated by a second scFv, directed against/capable of interacting with a further molecule/compound.
- further molecules/compounds may comprise cell surface molecules, tumor markers, tumor antigens and the like.
- Such further compounds/molecules are exemplified herein below and specific constructs are also given and provided in the appended examples.
- bispecific single chain antibody construct relates to a construct comprising two antibody derived binding domains, preferably scFvs.
- One of said binding domains consists of variable regions (or parts thereof) of an antibody, antibody fragment or derivate thereof, capable of specifically binding to/interacting with human CD 3 antigen (target molecule 1).
- the second binding domain consists of variable regions (or parts thereof) of an antibody, antibody fragment or derivative thereof, capable of specifically binding to/interacting with another (human) antigen (target molecule 2) as defined below.
- said second binding domain is, in accordance with this invention, the Ig-derived second domain recited above which comprises an antigen-interaction-site with specificity for a cell surface molecule and/or a tumor specific marker.
- Said two domains/regions in the bispecific construct are preferably covalently connected to one another as a single chain.
- This connection can be effected either directly (domain 1 [specific for human CD3 antigen, comprising a reduced propensity to generate T cell epitopes and comprising CDR-regions or CDR-regions and framework regions as defined above] - domain 2 [specific for a cell surface molecule and/or a tumor specific marker] or domain 1 [specific for a cell surface molecule and/or a tumor specific marker] - domain 2 [specific for human CD3 antigen, comprising a reduced propensity to generate T cell epitopes and comprising CDR- regions or CDR-regions and framework regions as defined above]) or through an additional polypeptide linker sequence (domainl - linker sequence - domain2).
- the linker is preferably of a length and sequence sufficient to ensure that each of the first and second domains can, independently from one another, retain their differential binding specificities.
- the CD3 specific binding construct comprising at least two domains as defined herein is a "bispecific single chain antibody construct", most preferably a bispecific single chain Fv (scFv). It is in particular envisaged that said construct is employed in context of a pharmaceutical composition. Bispecific single chain molecules are known in the art and are described in WO 99/54440, Mack, J. Immunol.
- a particularly preferred molecular format of the invention provides a polypeptide construct wherein the CD3 specific binding domain of the construct of the invention comprises at least one V ⁇ and one V ⁇ _ region as defined above.
- said specific binding construct may comprise additional regions/domains with reduced propensity to generate T cell epitopes.
- the VL-region and/or the corresponding frameworks may comprise amino acid stretches which have been engineered in accordance with this invention to having reduced propensity for T cell epitope generation.
- the intramolecular orientation of the V H -domain and the V L -domain, which are linked to each other by a linker-domain, in the scFv format is not decisive for the recited bispecific single chain constructs.
- V H -domain - linker domain - V L -domain; V L -domain - linker domain - V H -domain) are particular embodiments of the recited bispecific single chain construct.
- a CD3 specific domain can be located N- or C-terminally in the bispecific molecule.
- VH and VL regions of each domain can be arranged in different orders (V H -VL O ⁇ V L -VH).
- single-chain as used in accordance with the present invention means that said first and second domain of the bispecific single chain construct are covalently linked, preferably in the form of a co-linear amino acid sequence encoded by a single nucleic acid molecule.
- construct of the invention may comprise, in addition to the herein defined first domain and the Ig-derived second domain (an) additional domain(s), e.g. for the isolation and/or preparation of recombinantly produced constructs.
- the Ig- derived second domain and/or (a) connecting linker-region(s) is (are) modified, for example humanized and/or also deimmunized.
- deimmunization approaches are in particular illustrated in WO 00/34317, WO 98/52976, WO 02/079415 or WO 02/012899 and the appended examples. These approaches entail carrying out substitutions of amino acids within potential T cell epitopes. In this way, the likelihood that a given sequence will give rise to T cell epitopes upon intracellular protein processing is reduced.
- WO 92/10755 describes an approach in which antigenic determinants on proteins are engineered. Particularly, proteins are epitope mapped and their amino acid sequence is changed through genetic engineering.
- humanization approaches are well known in the art and in particular described for antibody molecules, e.g. Ig-derived molecules.
- the term “humanized” refers to humanized forms of non-human (e.g., murine) antibodies or fragments thereof (such as Fv, Fab, Fab', F(ab'), scFvs, or other antigen-binding partial sequences of antibodies) which contain some portion of the sequence derived from non-human antibody.
- Humanized antibodies include human immunoglobulins in which residues from a complementary determining region (CDR) of the human immunoglobulin are replaced by residues from a CDR of a non-human species such as mouse, rat or rabbit having the desired binding specificity, affinity and capacity.
- CDR complementary determining region
- the humanized antibody will comprise substantially all of at least one, and generally two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
- the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin ; see, inter alia, Jones et al., Nature 321 :522-525 (1986), Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).
- Fc immunoglobulin constant region
- a humanized antibody has one or more amino acids introduced into it from a source which is non-human in order to more closely resemble a human antibody, while still retaining the original binding activity of the antibody.
- Methods for humanization of antibodies/antibody molecules are further detailed in Jones et al., Nature 321 :522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); and Verhoeyen et al., Science 239:1534-1536 (1988).
- Specific examples of humanized antibodies, e.g. antibodies directed against EpCAM are known in the art, see e.g. ( oBuglio, Proceedings of the American Society of Clinical Oncology (Abstract).
- bispecific single chain antibody constructs are provided, which are deimmunized and can successfully be employed in pharmaceutical compositions.
- the Ig-derived second domain of the above-described CD3 specific binding construct may comprise an antigen-interaction-site with specificity for a cell surface molecule.
- cell surface molecule also denotes molecules which are presented on the surface of cells.
- the term “cell surface molecule”, relates to molecules, which are presented on the surface of cells and comprise domains or epitopes accessible (in vitro or in vivo) to Ig-derived binding domains, preferably antibodies, antibody fragments or derivatives. As illustrated above, most preferably said Ig-derived domain is a scFv.
- Examples for said cell surface molecules are membrane and transmembrane proteins, molecules adapted to said proteins or the cell surface etc.
- said cell surface molecule is a tumor specific marker.
- tumor specific marker relate to molecules, which are presented and/or located on the surface of tumor cells or which are ubiquitously expressed but are only accessible for binding of antibodies, antibody fragments or antibody derivatives on the surface of tumor cells.
- tumor markers are given herein below and comprise, but are not limited to, EpCAM, CD19, HER-2, HER-2 neu, HER-3, HER-4, EGFR, PSMA, CEA, MUC-1 (mucin), MUC2, MUC3, MUC4, MUC5 AC , MUC5 B , MUC7, Lewis-Y, CD20, CD33, CD30, CD44v6, Wue-1 , Plasma Cell Antigen (see WO 01/47953), (membrane-bound) IgE, Melanoma Chondroitin Sulfate Proteoglycan (MCSP), STEAP, mesothelin, Prostate Stem Cell Antigen (PSCA), sTn (sialylated Tn antigen), FAP
- the Ig-derived second domain of the CD3 specific binding construct of the invention may also comprise an antigen-interaction site with a specificity for a molecule selected from the group consisting of EpCAM, CCR5, CD19, HER-2, HER-2 neu, HER-3, HER-4, EGFR, PSMA, CEA, MUC-1 (mucin), MUC2, MUC3, MUC4, MUC5 AC , MUC5 B , MUC7, ⁇ hCG, Lewis-Y, CD20, CD33, CD30, ganglioside GD3, 9- O-Acetyl-GD3, GM2, Globo H, fucosyl GM1 , Poly SA, GD2, Carboanhydrase IX (MN/CA IX), CD44v6, Sonic Hedgehog (Shh), Wue-1, Plasma Cell Antigen, (membrane-bound) IgE, Melanoma Chondroitin Sulfate Proteoglycan (MCSP), CCR8, TNF-alpha
- tumorous diseases and/or lymphomas may be treated with an inventive deimmunized (bispecific) construct directed against human CD3 and CD20 (CD3xCD20 or CD20xCD3).
- inventive deimmunized (bispecific) construct directed against human CD3 and CD20 CD3xCD20 or CD20xCD3.
- Autoimmune diseases may be treated by the administration of deimmunized (bispecific) constructs directed against human CD3 and CD30 or CD19 (i.e CD3xCD30 or CD30xCD3 or CD3xCD19 or CD19xCD3).
- Rheumatoid arthritis, as well as other inflammatory diseases may be treated with an inventive deimmunized (bispecific) construct directed against human CD3 and CCR5 (CD3xCCR5 or CCR5xCD3).
- a deimmunized CD3 specific binding construct as defined herein and comprising a second Ig-derived domain directed to/binding with TNF-alpha precursor may also be useful in the treatment or prevention of inflammatory disorders.
- CD3 constructs as provided herein and comprising a second, Ig-derived domain directed against/binding to/interacting with EpCAM, CD19, HER-2, HER-2 neu, HER-3, HER-4, EGFR, PSMA, CEA, MUC-1 (mucin), MUC2, MUC3, MUC4, MUC5 AC , MUC5 B , MUC7, Lewis-Y, CD20, CD33, CD30, CD44v6, Wue-1, Plasma Cell Antigen (see WO 01/47953), (membrane- bound) IgE, Melanoma Chondroitin Sulfate Proteoglycan (MCSP), STEAP, mesothelin, Prostate Stem Cell Antigen (PSCA), sTn (sialylated Tn antigen), FAP (fibroblast activation antigen), EGFRvlll, Igoc, Ig ⁇ , MT-MMPs, Cora antigen, EphA2, L6 and CO-29 may be particularly useful in
- the administration of the CD3 binding constructs is also indicated for minimal residual disease, preferably for early solid tumors, advanced solid tumors or metastatic solid tumors.
- a particularly preferred CD3 specific binding construct of the invention comprises the above defined first domain with reduced propensity to generate T cell epitopes and a second, Ig-derived domain comprising an antigen-interaction site with a specificity for EpCAM.
- Epithelial cell adhesion molecule (EpCAM, also called 17-1 A antigen, KSA, EGP40, GA733-2, ks1-4 or esa) is a 40-kDa membrane-integrated glycoprotein of 314 amino acids with specific expression in certain epithelia and on many human carcinomas (reviewed in Balzar, J. Mol. Med. 1999, 77, 699-712). EpCAM was discovered and subsequently cloned through its recognition by the murine monoclonal antibody 17- 1A/edrecolomab (Goettlinger, Int J Cancer. 1986; 38, 47-53 and Simon, Proc. Natl. Acad. Sci. USA. 1990; 87, 2755-2759).
- EpCAM serves to adhere epithelial cells in an oriented and highly ordered fashion (Litvinov, J Cell Biol. 1997, 139, 1337-1348). Upon malignant transformation of epithelial cells the rapidly growing tumor cells are abandoning the high cellular order of epithelia. Consequently, the surface distribution of EpCAM becomes less restricted and the molecule better exposed on tumor cells and accessible for binding of antibodies, antibody fragments or antibody derivatives on the surface of tumor cells. Due to their epithelial cell origin, tumor cells from most carcinomas still express EpCAM on their surface.
- EpCAM In vivo, expression of EpCAM is related to increased epithelial proliferation and negatively correlates with cell differentiation (for review see Balzar, 1999, J. Mol. Med. 77, 699-712). Expression of EpCAM is essentially seen with all major carcinomas (reviewed in Balzar, J Mol Med. 1999, 77, 699-712 or documented, inter alia, in De Bree, Nucl Med Commun. 1994, 15, 613-27; Zhang, Clin Cancer Res. 1998, 4, 295-302). Because of its widespread expression, EpCAM is referred to as a "pan-carcinoma" antigen. In many cases, tumor cells were observed to express EpCAM to a much higher degree than their parental epithelium or less aggressive forms of said cancers.
- EpCAM expression represents an early event in the development of prostate cancer (Poczatek, J Urol., 1999, 162, 1462-1644).
- a strong EpCAM expression correlates with an increased proliferation and the disappearance of markers for terminal differentiation (Litvinov, Am. J. Pathol. 1996, 148, 865-75).
- overexpression of EpCAM on tumor cells is a predictor of survival (Gastl, Lancet. 2000, 356, 1981-1982).
- EpCAM is a marker for the detection of disseminated tumor cells in patients suffering from squamous cell carcinoma of the head, neck and lung (Chaubal, Anticancer Res 1999, 19, 2237- 2242, Piyathilake, Hum Pathol. 2000, 31 , 482-487).
- Normal squamous epithelium, as found in epidermis, oral cavity, epiglottis, pharynx, larynx and esophagus did not significantly express EpCAM (Quak, Hybridoma, 1990, 9, 377-387).
- EpCAM has been shown to be expressed on the majority of primary, metastatic, and disseminated NSCLC (non small cell lung cancer cells (Passlick, Int J Cancer, 2000, 87, 548-552)), on gastric and gastro-oesophageal junction adenocarcinomas (Martin, J Clin Pathol 1999, 52, 701-4) and in cell lines derived from colorectal, pancreatic carcinomas and breast carcinomas (Szala, Proc Natl Acad Sci U S A 1990, 87, 3542- 6, Packeisen, Hybridoma, 1999, 18, 37-40).
- the CD3 specific binding construct of the invention which comprises a second Ig-derived domain directed against/binding to EpCAM, comprises an amino acid sequence selected from the group of
- the present invention provides, in a particularly preferred embodiment for specific CD3 constructs which comprise a CD3 binding/interaction part ("anti- CD3") which has reduced propensity to generate T cell epitopes and a further single chain part (an Ig-derived domain) which specifically interacts with/binds to EpCAM ("anti-EpCAM").
- the following tables 1A, 1 B, 2A, 2B, 3A, 3B, 4A, 4B, 5A and 5B relate to preferred configurations of such CD3 and EpCAM binding constructs.
- EpCAM 3-1 , EpCAM 3-5, EpCAM 4-1 , EpCAM 4-7 and EpCAM 5-10 relate to specific single chain antibodies against EpCAM isolated by phage display in WO99/25818.
- Each protein construct in Tables 1A, 2A, 3A, 4A and 5A comprises 7 distinct protein modules, denoted A-G.
- Protein modules A-G are directly and covalently linked to one another in a single contiguous polypeptide chain by peptide bonds in the order A-B- C-D-E-F-G, with protein module A at the N-terminus and protein module G at the C- terminus.
- Protein modules A, C, E and G denote antibody variable domains which can be either VH or VL domains of antibodies having specificity for the human CD3 or EpCAM antigen.
- the modules B, D and F are linkers connecting the VH and VL domains.
- protein module A is a VH antibody domain
- protein module C is a VL protein domain, and vice versa.
- protein module E is a VH antibody domain
- protein module G is a VL protein domain, and vice versa.
- Deimmunized VH domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 74 or 76.
- Deimmunized VL domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 78, 80 or 82.
- the VH protein domain of human EpCAM 3-1 , 3-5, 4-1 , 4-7 and 5-10 antibody is as set out in SEQ ID NO.: 137, 141 , 145, 149 and 133, respectively.
- the VL protein domain of human EpCAM 3-1 , 3-5, 4-1 , 4-7 and 5-10 antibody is as set out in SEQ ID NO.: 139, 143, 147, 151 and 135, respectively.
- Pairs of antibody variable domains denoted by the protein module pairs A/C and E/G are joined by additional linking protein modules, wherein protein module B serves to directly link the module pair A/C and protein module F serves to directly link the module pair E/G.
- protein module B serves to directly link the module pair A/C
- protein module F serves to directly link the module pair E/G.
- the module pair A/C or E/G is a pair of deimmunized VH/VL or VL/VH protein domains from an antibody having specificity for the human CD3 antigen
- protein module B or F respectively, has the amino acid sequence as set out in SEQ ID NO.: 3.
- module pair A/C or E/G is a pair of VH/VL or VL/VH from an antibody having specificity for the EpCAM antigen
- protein module B or F has the amino acid sequence as set out in SEQ ID NO.: 168.
- the module D connects the ABC and EFG module groups.
- the combination of protein modules A-B-C and the combination of protein modules E-F-G each respectively constitute one scFv fragment of an antibody having specificity for either the human CD3 antigen or for the EpCAM antigen. If the modules A and C show the CD3 binding sequence, the respective groups of protein modules A-B-C and E-F-G are connected to each other through protein module D, having the sequence as set out in SEQ ID NO.: 176. On the other hand, if the modules A and C show the EpCAM binding sequence, the respective groups of protein modules A-B-C and E-F-G are connected to each other through protein module D, having the sequence as set out in SEQ ID NO.: 174.
- Protein module D serves to connect the C-terminal end of protein module C with the N-terminal end of protein module E.
- Each nucleic acid construct in Tables 1 B, 2B, 3B, 4B and 5B comprises 7 distinct nucleic acid modules, denoted A-G.
- Nucleic acid modules A-G are directly and covalently linked to one another in a single contiguous nucleotide chain by phosphate glycoside bonds in the order A-B-C-D-E-F-G, with nucleic acid module A at the 5'- end and nucleic acid module G at the 3'-end of a respective nucleic acid construct.
- Nucleic acid modules A, C, E and G denote encoding regions for antibody variable domains which can be either VH or VL domains of antibodies having specificity for the human CD3 or EpCAM antigen.
- nucleic acid module A encodes a VH antibody domain
- nucleic acid module C encodes a VL protein domain, and vice versa.
- nucleic acid module E encodes a VH antibody domain
- nucleic acid module G encodes a VL protein domain, and vice versa.
- Nucleic acid molecules encoding deimmunized VH domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 73 or 75.
- Nucleic acid molecules encoding deimmunized VL domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 77, 79 or 81.
- the nucleic acid molecule encoding the VH protein domain of the human EpCAM 3-1 , 3-5, 4-1 , 4-7 and 5-10 antibody is as set out in SEQ ID NO.: 136, 140, 144, 148 and 132 respectively.
- the nucleic acid molecule encoding the VL protein domain of the human EpCAM 3-1 , 3-5, 4-1 , 4-7 and 5-10 antibody is as set out in SEQ ID NO.: 138, 142, 146, 150 and 134, respectively.
- nucleic acid module pairs A/C and E/G Pairs of nucleic acids encoding antibody variable domains denoted by the nucleic acid module pairs A/C and E/G are joined by additional linking nucleic acid modules, wherein nucleic acid module B serves to directly link the module pair A/C and nucleic acid module F serves to directly link the module pair E/G.
- nucleic acid module B or F has the nucleotide sequence as set out in SEQ ID NO.: 202.
- nucleic acid module B or F has the nucleotide sequence as set out in SEQ ID NO.: 201.
- nucleic acid modules A-B-C and the combination of nucleic acid modules E-F-G each respectively constitute one scFv fragment of an antibody having specificity for either the human CD3 antigen or for the EpCAM antigen.
- the respective groups of nucleic acid modules A-B-C and E-F-G are connected to each other through nucleic acid module D, having the nucleotide sequence as set out in SEQ ID NO.: 175.
- the respective groups of nucleic acid modules A-B-C and E-F-G are connected to each other through nucleic acid module D, having the nucleotide sequence as set out in SEQ ID NO.: 173.
- nucleic acid module D serves to connect the 3'-end of nucleic acid module C with the 5'-end of nucleic acid module E.
- Table 1A Deimmunized anti-human CD3 constructs comprising single chain anti-EpCAM 3-1 variable regions: amino acid sequence
- Table 1B Deimmunized anti-human CD3 constructs comprising single chain anti-EpCAM 3-1 variable regions: nucleotide sequence
- Table 2A Deimmunized anti-human CD3 constructs comprising single chain anti-EpCAM 3-5 variable regions: amino acid sequence
- Table 2B Deimmunized anti-human CD3 constructs comprising single chain anti-EpCAM 3-5 variable regions: nucleotide sequence
- Table 3A Deimmunized anti-human CD3 constructs comprising single chain anti-EpCAM 4-1 variable regions: amino acid sequence
- Table 3B Deimmunized anti-human CD3 constructs comprising single chain anti-EpCAM 4-1 variable regions: nucleotide sequence
- Table 4A Deimmunized anti-human CD3 constructs comprising single chain anti-EpCAM 4-7 variable regions: amino acid sequence
- Table 4B Deimmunized anti-human CD3 constructs comprising single chain anti-EpCAM 4-7 variable regions: nucleotide sequence
- Table 5A Deimmunized anti-human CD3 constructs comprising single chain anti-EpCAM 5-10 variable regions: amino acid sequence
- Table 5B Deimmunized anti-human CD3 constructs comprising single chain anti-EpCAM 5-10 variable regions: nucleotide sequence
- the invention provides bispecific antibody constructs comprising a specificity binding to CD3 and EpCAM and having the SEQ ID NO.:30, 31 (construct 2 of Table 1A and 1B), Seq ID NO.: 48, 49 (construct 5 of the Table 1A, 1B), SEQ ID NO.: 64, 65 (construct 2 of Table 2A, 2B), SEQ ID NO.: 54, 55 (construct 5 of Table 2A, 2B), Seq ID NO.: 66, 67 (construct 2 of Table 3A, 3B), SEQ ID NO.: 32, 33 (construct 2 of Table 4A, 4B), SEQ ID NO.:34, 35 (construct 4 of Table 4A, 4B), SEQ ID NO.: 60, 61 (construct 5 of Table 4A, 4B), SEQ ID NO.: 36, 37 (construct 2 of Table 5A, 5B), SEQ ID NO.: 38, 39 (construct 4 of Table 5A, 5B) or SEQ ID NO.:62, 63 (con
- CD3 and EpCAM binding constructs of the invention comprising at least the above described first domain with reduced propensity for T cell epitope generation and specificity for human CD3 and a second, Ig-derived domain which is specific for EpCAM are shown in SEQ ID NOs.: 31 , 33, 35, 37, 39, 49, 55, 58, 61 , 63, 65, 67, 237, 239, 241 , 243, 245, 247, 249, 251 , 253, 255, 257, 259, 261 , 263, 265, 267, 269, 271 , 273, 275, 277, 279, 281 , 283, 285, 287, 289, 291 , 293, 295, 297, 299, 301 , 303, 305, 307, 309, 311 , 313, 315, 317, 319, 321 , 323 and 325.
- Corresponding nucleic acid molecules encoding said preferred CD3 and EpCAM binding constructs as defined herein comprise SEQ ID NOs.: 30, 32, 34, 36, 38, 48, 54, 57, 60, 62, 64, 66, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322 and 324.
- the present invention also provides for CD3 specific binding constructs comprising a first domain which specifically binds to human CD3 and has reduced propensity to generate T cell epitopes and comprising an Ig-derived second domain directed against/capable of binding to EpCAM, selected from the group consisting of
- the present invention also provides for CD3 specific binding constructs comprising a first domain which specifically binds to human CD3 and has reduced propensity to generate T cell epitopes and comprising an Ig-derived second domain directed against/ capable of binding to EpCAM, which comprise an amino acid sequence encoded by a nucleic acid sequence hybridizing with the complementary strand of a nucleic acid sequence as defined in (b) herein above, i.e.
- nucleic acid sequence as shown in any one of SEQ ID NO.: 30, 32, 34, 36, 38, 48, 54, 57, 60, 62, 64, 66, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322 or 324 under stringent hybridization conditions.
- hybridizing refers to polynucleotides/nucleic acid sequences which are capable of hybridizing to the polynucleotides encoding the deimmunized constructs as defined herein. Therefore, said polynucleotides may be useful as probes in Northern or Southern Blot analysis of RNA or DNA preparations, respectively, or can be used as oligonucleotide primers in PCR analysis dependent on their respective size.
- said hybridizing polynucleotides comprise at least 10, more preferably at least 15 nucleotides in length while a hybridizing polynucleotide of the present invention to be used as a probe preferably comprises at least 100, more preferably at least 200, or most preferably at least 500 nucleotides in length.
- hybridization conditions are referred to in standard text books such as Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (2001) N.Y.
- Preferred in accordance with the present inventions are polynucleotides which are capable of hybridizing to the polynucleotides of the invention or parts thereof, under stringent hybridization conditions.
- “Stringent hybridization conditions” refer, i.e. to an overnight incubation at 42°C in a solution comprising 50% formamide, 5x SSC (750 mM NaCI, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 ⁇ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1 x SSC at about 65°C. Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the invention at lower stringency hybridization conditions.
- Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature.
- washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).
- blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations.
- the inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.
- the recited nucleic acid molecules may be, e.g., DNA, cDNA, RNA or synthetically produced DNA or RNA or a recombinantly produced chimeric nucleic acid molecule comprising any of those polynucleotides either alone or in combination.
- the deimmunized CD3 and EpCAM binding constructs provided in this invention are particularly useful in medical settings, for example in the prevention, treatment and/or the amelioration of tumorous diseases, in particular, breast cancer, colon cancer, prostate cancer, head and neck cancer, skin cancer (melanoma), cancers of the genito-urinary tract, e.g.
- the deimmunized constructs binding CD3 and EpCAM can be used for the treatment of epithelial cancer, preferably adenocarcinomas, or minimal residual disease, more preferably early solid tumor, advanced solid tumor or metastatic solid tumor.
- said construct comprises a second Ig-derived domain which comprises an antigen-interaction site with a specificity for CCR5.
- the chemokine receptor CCR5 is a member of a large family of G protein coupled seven transmembrane domain receptors that binds the proinflammatory chemokines RANTES, MIP1- ⁇ , MIP1- ⁇ and MCP-2. Chemokines act in concert with adhesion molecules to induce the extravasation of leukocytes and to direct their migration to sites of tissue injury. CCR5 is expressed on a minority of T-cells and monocytes and is further the major co-receptor for M-trophic HIV-1 strains that predominate early in the course of an HIV-infection.
- HIV Human immunodeficiency virus
- CD4 Human immunodeficiency virus
- CCR5 The co-receptor that is initially recognized is CCR5
- CXCR4 the co-receptor for HIV-1
- M-tropic viruses The HIV-1 strains that cause most transmissions of viruses by sexual contact are called M-tropic viruses.
- HIV-1 strains also known as non-syncytia inducing (NSI) primary viruses
- NBI non-syncytia inducing
- the T-tropic viruses can also replicate in primary CD4+ T-cells but can in addition infect established CD4+ T-cell lines in vitro, which they do via the chemokine receptor CXCR4 (fusin).
- T- tropic strains can use CCR5 in addition to CXCR4, and some can enter macrophages via CCR5, at least under certain in vitro conditions (D'Souza, Nature Med. 2, 1293 (1996); Premack, Nature Med. 2, 1174; Fauci, Nature 384, 529 (1996)). Whether other coreceptors contribute to HIV-1 pathogenesis is unresolved, but the existence of another coreceptor for some T-tropic strains can be inferred from in vitro studies.
- CCR5 is the predominant coreceptor for the virus in patients; transmission (or systemic establishment) of CXCR4-using (T-tropic) strains is rare (D'Souza, Nature Med. 2, 1293 (1996); Premack, Nature Med. 2, 1174; Fauci, Nature 384, 529 (1996), Paxton, Nature Med. 2, 412 (1996); Liu, Cell 86, 367 (1996); Samson, Nature 382, 722 (1996); Dean, Science 273, 1856 (1996); Huang, Nature Med. 2, 1240 (1996)).
- SI viruses evolve in vivo (or if they are transmitted), they are especially virulent and cause faster disease progression (D'Souza, Nature Med.
- CCR5 and CXCR3 are predominantly expressed on T-cells infiltrating demyelinating brain lesions, as well as in the peripheral blood of affected patients. Elimination of the T-cells would block the T-cell arm of this autoimmune disease.
- CCR3 and CCR5 were also observed in T cells and B cells of lymph nodes derived from patients with Hodgkin's disease. Diabetes type I is considered to be a T-cell mediated autoimmune disease.
- the expression of CCR5 receptor in the pancreas was associated with the progression of type I diabetes in relevant animal models (Cameron (2000) J. Immunol. 165, 1102- 1110). In particular, the CCR5 expression was associated with the development of insulinitis and spontaneous type I diabetes.
- CCR5 antibodies specifically binding to (human) CCR5 are known in the art and comprise, MC-1 (Mack (1998) J. Exp. Med. 187, 1215-1224 or MC-5 (Blanpain (2002) Mol Biol Cell. 13:723-37, Segerer (1999) Kidney Int. 56:52-64, Kraft (2001) J Biol Chem. 14;276:34408-18).
- the CCR-5 antibodies, in particular MC-1 and MC-5 may serve as a source for Ig-derived second domain of the CD3 specific construct of the invention.
- the invention relates to a bispecific construct comprising at least two domains, wherein the first domain provides for the specificity to human CD3 and has a reduced propensity to generate T cell epitopes and whereby said Ig-derived second domain is derived from an antibody specific for (human) CCR5.
- a construct is a single chain scFV as defined herein .
- the CD3 specific construct of this invention comprises, for example, VL and VH domains of an antibody (i.e. an Ig-derived second domain) specific for CCR5, preferably the human CCR5, and VH and VL domains of an antibody specific for the CD3 antigen.
- Said antibody specific for the human CCR5 is the murine anti-human CCR5 antibody MC- 1 , described, inter alia, in Mack (1998), J. Exp. Med. 187, 1215-1224 and in the appended examples.
- CD3-specific binding constructs comprise a deimmunized domain directed against/binding to/interacting with human CD3 and a second Ig-derived domain which specifically binds to/interacts with CCR5.
- Such constructs are shown in Table 6A and 6B.
- the modules A-G in Tables 6A and 6B can be defined as mentioned above for Tables 1-5.
- Deimmunized VH domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 74 or 76.
- Deimmunized VL domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 78, 80 or 82.
- the VH protein domain of human CCR5 antibody is as set out in SEQ ID NO.: 129.
- the VL protein domain of human CCR5 antibody is as set out in SEQ ID NO.: 131.
- protein module B or F has the amino acid sequence as set out in SEQ ID NO.: 3.
- protein module B or F When either the module pair A/C or E/G is a pair of VH/VL or VL/VH from an antibody having specificity for the EpCAM antigen, protein module B or F, respectively, has the amino acid sequence as set out in SEQ ID NO.: 168.
- the respective groups of protein modules A-B-C and E-F-G are connected to each other through protein module D, having the sequence as set out in SEQ ID NO.: 174.
- an additional serine may be introduced for cloning purposes (linker as depicted in SEQ ID NO.:176) between the VL and subsequent V domain.
- Nucleic acid molecules encoding deimmunized VH domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 73 or 75.
- Nucleic acid molecules encoding deimmunized VL domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 77, 79 or 81.
- the nucleic acid molecule encoding the VH protein domain of the human CCR5 antibody is as set out in SEQ ID NO.: 128.
- the nucleic acid molecule encoding the VL protein domain of the human CCR5 antibody is as set out in SEQ ID NO.: 130.
- nucleic acid module B or F When either the module pair A C or E/G denotes nucleic acid encoding a pair of deimmunized VH/VL or VL/VH protein domains from an antibody having specificity for the human CD3 antigen, nucleic acid module B or F, respectively, has the nucleic acid sequence as set out in SEQ ID NO.: 202.
- nucleic acid module B or F When either the module pair A/C or E/G denotes nucleic acid enconding a pair of VH/VL or VL/VH from an antibody having specificity for the CCR5 antigen, nucleic acid module B or F, respectively, has the nucleic acid sequence as set out in SEQ ID NO.: 201.
- the groups of nucleic acid modules A-B-C and E-F-G are connected to each other through protein module D, having the sequence as set out in SEQ ID NO.: 173.
- An alternative linker SEQ ID NO.: 175 may also be used to conjugate VL domain with a subsequent V domain (including an additional codon encoding a serine residue for cloning purposes).
- Table 6B Deimmunized anti-human CD3 constructs comprising single chain anti-CCR5 variable regions: nucleic acid sequence
- said constructs comprise an amino acid sequence selected from the group of
- the CCR5 and CD3 binding constructs SEQ ID NO.:206, 208, 210 represent construct 5 and SEQ ID NO.:212, 214 and 216 represent construct 13 of Table 6 and have the three different VL regions (VL1 (SEQ ID NO.:78), VL2 (SEQ ID NO.:80), or VL3 (SEQ ID NO.:82).
- the present invention also provides for CD3 specific binding constructs comprising a first domain which specifically binds to human CD3 and has reduced propensity to generate T cell epitopes and comprising an Ig-derived second domain directed against/ capable of binding to CCR5, which comprise an amino acid sequence encoded by a nucleic acid sequence hybridizing with the complementary strand of a nucleic acid sequence as defined in (b) herein above, i.e. to a nucleic acid sequence as shown in any one of SEQ ID NO.: 205, 207, 209, 211 , 213 or 215 under stringent hybridization conditions.
- hybridization and “stringent conditions” have been described herein above. The corresponding definitions and embodiments apply here mutatis mutandis.
- the deimmunized CD3 and CCR5 binding constructs provided herein are particularly useful in the medical intervention of viral disease, in particular HIV infections and AIDS, or of autoimmune diseases and/or inflammatory diseases, like rheumatoid arthritis.
- the present invention provides for CD3 specific binding constructs as defined herein above, wherein the Ig-derived second domain of the inventive construct comprises an antigen-interaction site with specificity for CD 19.
- CD19 has proved to be a very useful medical target.
- CD19 is expressed in the whole B cell lineage from the pro B cell to the mature B cell, it is not shed, is uniformly expressed on all lymphoma cells, and is absent from stem cells (Haagen, Clin Exp Immunol 90 (1992), 368-75; Uckun, Proc. Natl. Acad. Sci. USA 85 (1988), 8603-7).
- Combination therapy employing both an antibody directed against CD19 and an additional immunoregulatory antibody has been disclosed for the treatment of B cell malignancies (WO 02/04021, US2002006404, US2002028178) and autoimmune diseases (WO 02/22212, US2002058029).
- WO 00/67795 discloses the use i.a.
- B-ALL B cell acute lymphatic leukemia
- pre-B-ALL B cell precursor acute lymphatic leukemia
- B-CLL B cell chronic lymphatic leukemia
- CD3-specific binding constructs which comprise an deimmunized domain directed against/binding to/interacting with human CD3 and a second Ig-derived domain which specifically binds to/interacts with CD19.
- Such constructs are shown in Tables 7A and 7B.
- the modules A-G in Tables 7A and 7B can be defined as mentioned above for Tables 1-5.
- Deimmunized VH domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 74 or 76.
- Deimmunized VL domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 78, 80 or 82.
- the VH protein domain of human CD19 antibody is as set out in SEQ ID NO.: 114.
- the VL protein domain of human CCR5 antibody is as set out in SEQ ID NO.: 116.
- protein module B or F has the amino acid sequence as set out in SEQ ID NO.: 3.
- protein module B or F When either the module pair A/C or E/G is a pair of VH/VL or VL/VH from an antibody having specificity for the CD19 antigen, protein module B or F, respectively, has the amino acid sequence as set out in SEQ ID NO.: 168.
- the respective groups of protein modules A-B-C and E-F-G are connected to each other through protein module D, having the sequence as set out in SEQ ID NO.: 174.
- an additional serine may be introduced for cloning purposes (linker as depicted in SEQ ID NO.:176) between the VL and subsequent V domain.
- Nucleic acid molecules encoding deimmunized VH domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 73 or 75.
- Nucleic acid molecules encoding deimmunized VL domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 77, 79 or 81.
- the nucleic acid molecule encoding the VH protein domain of the human CD19 antibody is as set out in SEQ ID NO.: 113.
- the nucleic acid molecule encoding the VL protein domain of the human CCR5 antibody is as set out in SEQ ID NO.: 115.
- nucleic acid module B or F has the amino acid sequence as set out in SEQ ID NO.: 202.
- nucleic acid module B or F has the nucleic acid sequence as set out in SEQ ID NO.: 201.
- the groups of nucleic acid modules A-B-C and E-F-G are connected to each other through protein module D, having the sequence as set out in SEQ ID NO.: 173.
- An alternative linker SEQ ID NO.: 175 may also be used to conjugate VL domain with a subsequent V domain (including an additional codon encoding a serine residue for cloning purposes).
- Table 7A Deimmunized anti-human CD3 constructs comprising single chain anti-CD19 variable regions: amino acid sequence
- the present invention provides for a deimmunized CD3-specific binding construct which comprises a CD3-binding domain as defined above and a second, Ig-derived domain which specifically binds to/interacts with CD 19, preferably human CD 19, wherein said CD3-specific binding construct comprises an amino acid sequence selected from the group of
- Preferred CD19 and CD3 binding constructs according to the invention are SEQ ID NO.:190, 192, 194 representing construct 5 and SEQ ID NO.:196, 198 and 200 representing construct 13 of Table 7 and having the three different VL regions (VL1 (SEQ ID N0..78), VL2 (SEQ ID NO..80), or VL3 (SEQ ID NO.:82)).
- the present invention also provides for CD3 specific binding constructs comprising a first domain which specifically binds to human CD3 and has reduced propensity to generate T cell epitopes and comprising an Ig-derived second domain directed against/capable of binding to CD19, which comprise an amino acid sequence encoded by a nucleic acid sequence hybridizing with the complementary strand of a nucleic acid sequence as defined in (b) herein above, i.e.
- the herein disclosed deimmunized CD3 and CD19 binding constructs are particularly useful in the prevention, treatment or amelioration of a proliferative disease, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, a viral disease, allergic reactions, parasitic reactions, graft-versus-host diseases, host-versus-graft diseases or B-cell malignancies, in particular B cell non-Hodgkin's lymphoma, Hodgkin's lymphoma or B cell leukemias (e.g. B cell acute lymphoatic leukemia (B-ALL), (e.g. hairy cell lymphoma) B cell precursor acute lymphatic leukemia (pre-B-ALL), B cell chronic lymphatic leukemia (B-CLL)) leukemia.
- B-ALL B cell acute lymphoatic leukemia
- pre-B-ALL pre-B-ALL
- B-CLL B cell chronic lymphatic leukemia
- the present invention relates to a CD3 specific binding construct as defined above comprising a first domain specifically binding to human CD3 and having reduced propensity to generate T cell epitopes and a second domain, wherein said second domain is Ig-derived and comprises an antigen- interaction site with a specificity for CD20.
- CD20 is one of the cell surface proteins present on B-lymphocytes.
- CD20 antigen is found in normal and malignant pre-B and mature B lymphocytes, including those in over 90% of B-cell non-Hodgkin's lymphomas (NHL). The antigen is absent in hematopoetic stem cells, activated B lymphocytes (plasma cells) and normal tissue.
- Several antibodies mostly of murine origin have been described: 1 F5 (Press et al., 1987, Blood 69/2, 584-591), 2B8 / C2B8, 2H7, 1 H4 (Liu et al., 1987, J Immunol 139, 3521-3526; Anderson et al., 1998, US patent No. 5,736,137; Haisma et al., 1998, Blood 92, 184-190; Shan et al., 1999, J. Immunol 162, 6589-6595).
- CD20 has been described in immunotherapeutic strategies for the treatment of plasma cell malignancies using vaccination with DNA encoding scFv linked to carrier protein (Treon et al., 2000, Semin Oncol 27(5), 598) and in immunotherapeutic treatment using CD20 antibodies (IDEC-C2B8) have been shown to be effective in the treatment of non-Hodgkin's B-cell lymphoma.
- CD20 antibodies have proven efficacy and tolerability in non-Hodgkin's lymphoma, achieving response rates of 73% and 48% in previously untreated or relapsed/refractory indolent non-Hodgkin's lymphoma, respectively (Montserrat, 2003, Semin Oncol 30(1suppl2), 34-39).
- CD20 antibodies have been widely used to treat relapsing or advanced stage B-cell neoplasms with an efficacy of about 50%.
- CD3-specific binding constructs comprise a deimmunized domain directed against/binding to/interacting with human CD3 and a second Ig-derived domain which specifically binds to/interacts with CD20.
- Such constructs are shown in Tables 8A and 8B.
- the modules A-G in Tables 8A and 8B can be defined as mentioned above for Tables 1-5.
- Deimmunized VH domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 74 or 76.
- Deimmunized VL domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 78, 80 or 82.
- the VH protein domain of human CD20 antibody is as set out in SEQ ID NO.: 170.
- the VL protein domain of human CD20 antibody is as set out in SEQ ID NO.: 172.
- protein module B or F has the amino acid sequence as set out in SEQ ID NO.: 3.
- protein module B or F When either the module pair A/C or E/G is a pair of VH/VL or VL/VH from an antibody having specificity for the CD20 antigen, protein module B or F, respectively, has the amino acid sequence as set out in SEQ ID NO.: 168.
- the respective groups of protein modules A-B-C and E-F-G are connected to each other through protein module D, having the sequence as set out in SEQ ID NO.: 174.
- an additional serine may be introduced for cloning purposes (linker as depicted in SEQ ID NO.:176) between the VL and subsequent V domain.
- Nucleic acid molecules encoding deimmunized VH domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 73 or 75.
- Nucleic acid molecules encoding deimmunized VL domains of antibodies having specificity for the human CD3 antigen can be selected from the sequences as set out in SEQ ID NOs.: 77, 79 or 81.
- the nucleic acid molecule encoding the VH protein domain of the human CD20 antibody is as set out in SEQ ID NO.: 169.
- the nucleic acid molecule encoding the VL protein domain of the human CD20 antibody is as set out in SEQ ID NO.: 171.
- nucleic acid module B or F has the amino acid sequence as set out in SEQ ID NO.: 202.
- nucleic acid module B or F has the nucleic acid sequence as set out in SEQ ID NO.: 201.
- nucleic acid modules A-B-C and E-F-G are connected to each other through nucleic acid module D, having the sequence as set out in SEQ ID NO.: 173.
- An alternative linker SEQ ID NO.:175 may also be used to conjugate VL domain with a subsequent V domain (including an additional codon encoding a serine residue for cloning purposes).
- Table 8A Deimmunized anti-human CD3 constructs comprising single chain anti-CD20 variable regions: amino acid sequence
- the deimmunized CD3 and CD20 binding constructs of the present invention comprises an amino acid sequence which is selected from the group consisting of
- the present invention also provides for CD3 specific binding constructs comprising a first domain which specifically binds to human CD3 and has reduced propensity to generate T cell epitopes and comprising an Ig-derived second domain directed against/capable of binding to CD20, which comprise an amino acid sequence encoded by a nucleic acid sequence hybridizing with the complementary strand of a nucleic acid sequence as defined in (b) herein above, i.e. to a nucleic acid sequence as shown in any one of SEQ ID NO.: 217, 219, 221 , 223, 225 or 227, under stringent hybridization conditions.
- hybridization and “stringent conditions” have been described herein above. The corresponding definitions and embodiments apply here mutatis mutandis.
- CD3 and CD20 binding constructs are envisaged for use in the treatment, prevention and/or amelioration of B-cell related disorders, preferably in the medical intervention of lymphoma, more preferably in the treatment of non-Hodgkin lymphoma.
- the invention also provides for nucleic acid sequence encoding a CD3 specific binding molecule of the invention.
- regulatory sequences may be added to the nucleic acid molecule of the invention.
- promoters, transcriptional enhancers and/or sequences which allow for induced expression of the polynucleotide of the invention may be employed.
- a suitable inducible system is for example tetracycline-regulated gene expression as described, e.g., by Gossen and Bujard (Proc. Natl. Acad. Sci. USA 89 (1992), 5547-5551) and Gossen et al. (Trends Biotech. 12 (1994), 58-62), or a dexamethasone-inducible gene expression system as described, e.g. by Crook (1989) EMBO J. 8, 513-519 .
- nucleic acid molecules may contain, for example, thioester bonds and/or nucleotide analogues. Said modifications may be useful for the stabilization of the nucleic acid molecule against endo- and/or exonucleases in the cell.
- Said nucleic acid molecules may be transcribed by an appropriate vector containing a chimeric gene which allows for the transcription of said nucleic acid molecule in the cell.
- polynucleotide can be used for "gene targeting" or "gene therapeutic” approaches.
- nucleic acid molecules are labeled. Methods for the detection of nucleic acids are well known in the art, e.g., Southern and Northern blotting, PCR or primer extension. This embodiment may be useful for screening methods for verifying successful introduction of the nucleic acid molecules described above during gene therapy approaches.
- Said nucleic acid molecule(s) may be a recombinantly produced chimeric nucleic acid molecule comprising any of the aforementioned nucleic acid molecules either alone or in combination.
- the nucleic acid molecule is part of a vector.
- the present invention therefore also relates to a vector comprising the nucleic acid molecule described in the present invention.
- plasmids are known to those skilled in molecular biology, the choice of which would depend on the function desired and include plasmids, cosmids, viruses, bacteriophages and other vectors used conventionally in genetic engineering. Methods which are well known to those skilled in the art can be used to construct various plasmids and vectors; see, for example, the techniques described in Sambrook et al. (loc cit.) and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1989), (1994). Alternatively, the polynucleotides and vectors of the invention can be reconstituted into liposomes for delivery to target cells.
- a cloning vector was used to isolate individual sequences of DNA. Relevant sequences can be transferred into expression vectors where expression of a particular polypeptide is required.
- Typical cloning vectors include pBluescript SK, pGEM, pUC9, pBR322 and pGBT9.
- Typical expression vectors include pTRE, pCAL-n-EK, pESP-1 , pOP13CAT.
- said vector comprises a nucleic acid sequence which is a regulatory sequence operably linked to said nucleic acid sequence encoding a bispecific single chain antibody constructs defined herein.
- control elements are known to the artisan and may include a promoter, a splice cassette, translation initiation codon, translation and insertion site for introducing an insert into the vector.
- said nucleic acid molecule is operatively linked to said expression control sequences allowing expression in eukaryotic or prokaryotic cells.
- control sequence refers to DNA sequences, which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism. In prokaryotes, control sequences generally include promoter, ribosomal binding site, and terminators. In eukaryotes generally control sequences include promoters, terminators and, in some instances, enhancers, transactivators or transcription factors.
- control sequence is intended to include, at a minimum, all components the presence of which are necessary for expression, and may also include additional advantageous components.
- operably linked refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
- a control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
- the control sequence is a promoter, it is obvious for a skilled person that double-stranded nucleic acid is preferably used.
- the recited vector is preferably an expression vector.
- An "expression vector” is a construct that can be used to transform a selected host and provides for expression of a coding sequence in the selected host. Expression vectors can for instance be cloning vectors, binary vectors or integrating vectors.
- Expression comprises transcription of the nucleic acid molecule preferably into a translatable mRNA.
- Regulatory elements ensuring expression in prokaryotes and/or eukaryotic cells are well known to those skilled in the art. In the case of eukaryotic cells they comprise normally promoters ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript.
- Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the P , lac, trp or tac promoter in E.
- regulatory elements permitting expression in eukaryotic host cells are the AOX1 or GAL1 promoter in yeast or the CMV-, SV40-, RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells.
- Beside elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as the SV40-poly-A site or the tk-poly-A site, downstream of the polynucleotide.
- transcription termination signals such as the SV40-poly-A site or the tk-poly-A site, downstream of the polynucleotide.
- leader sequences capable of directing the polypeptide to a cellular compartment or secreting it into the medium may be added to the coding sequence of the recited nucleic acid sequence and are well known in the art; see also, e.g., appended example 1.
- the leader sequence(s) is (are) assembled in appropriate phase with translation, initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein, or a portion thereof, into the periplasmic space or extracellular medium.
- the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product; see supra.
- suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM ⁇ , pRc/CMV, pcDNAI , pcDNA3 (In-vitrogene), pEF-DHFR, pEF-ADA or pEF-neo (Raum et al. Cancer Immunol Immunother (2001) 50(3), 141-150) or pSPORTI (GIBCO BRL).
- the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming of transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used.
- the vector Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and as desired, the collection and purification of the polypeptide of the invention may follow; see, e.g., the appended examples.
- An alternative expression system which could be used is an insect system.
- Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae.
- the coding sequence of a recited nucleic acid molecule may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of said coding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect S.
- frugiperda cells or Trichoplusia larvae in which the protein of the invention is expressed (Smith, J. Virol. 46 (1983), 584; Engelhard, Proc. Nat. Acad. Sci. USA 91 (1994), 3224-3227).
- Additional regulatory elements may include transcriptional as well as translational enhancers.
- the above-described vectors of the invention comprises a selectable and/or scorable marker.
- Selectable marker genes useful for the selection of transformed cells and, e.g., plant tissue and plants are well known to those skilled in the art and comprise, for example, antimetabolite resistance as the basis of selection for dhfr, which confers resistance to methotrexate (Reiss, Plant Physiol. (Life Sci. Adv.) 13 (1994), 143-149); npt, which confers resistance to the aminoglycosides neomycin, kanamycin and paromycin (Herrera-Estrella, EMBO J. 2 (1983), 987-995) and hygro, which confers resistance to hygromycin (Marsh, Gene 32 (1984), 481-485).
- trpB which allows cells to utilize indole in place of tryptophan
- hisD which allows cells to utilize histinol in place of histidine
- mannose-6-phosphate isomerase which allows cells to utilize mannose
- ODC omithine decarboxylase
- DFMO omithine decarboxylase inhibitor
- Blasticidin S Teamura, Biosci. Biotechnol. Biochem. 59 (1995), 2336-2338).
- luciferase PI. Sci. 116 (1996), 59-72; Scikantha, J. Bact. 178 (1996), 121), green fluorescent protein (Gerdes, FEBS Lett. 389 (1996), 44-47) or ⁇ -glucuronidase (Jefferson, EMBO J. 6 (1987), 3901-3907).
- This embodiment is particularly useful for simple and rapid screening of cells, tissues and organisms containing a recited vector.
- nucleic acid molecule can be used alone or as part of a vector to express the encoded CD3 specific construct in cells, for, e.g., purification but also for gene therapy purposes.
- the nucleic acid molecules or vectors containing the DNA sequence(s) encoding any one of the above described (bispecific) CD3 constructs is introduced into the cells which in turn produce the polypeptide of interest.
- Gene therapy which is based on introducing therapeutic genes into cells by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer.
- Suitable vectors, methods or gene-delivery systems for in-vitro or in-vivo gene therapy are described in the literature and are known to the person skilled in the art; see, e.g., Giordano, Nature Medicine 2 (1996), 534-539; Schaper, Circ. Res. 79 (1996), 911-919; Anderson, Science 256 (1992), 808-813; Verma, Nature 389 (1994), 239; Isner, Lancet 348 (1996), 370-374; Muhlhauser, Circ. Res. 77 (1995), 1077-1086; Onodera, Blood 91 (1998), 30-36; Verma, Gene Ther. 5 (1998), 692-699; Nabel, Ann. N.Y. Acad. Sci.
- nucleic acid molecules and vectors may be designed for direct introduction or for introduction via liposomes, or viral vectors (e.g., adenoviral, retroviral) into the cell.
- said cell is a germ line cell, embryonic cell, or egg cell or derived therefrom, most preferably said cell is a stem cell.
- An example for an embryonic stem cell can be, inter alia, a stem cell as described in, Nagy, Proc. Natl. Acad. Sci. USA 90 (1993), 8424-8428.
- the present invention relates to methods to derive vectors, particularly plasmids, cosmids, viruses and bacteriophages used conventionally in genetic engineering that comprise a nucleic acid molecule encoding the polypeptide sequence of a bispecific single chain antibody construct defined herein.
- said vector is an expression vector and/or a gene transfer or targeting vector.
- Expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or bovine papilloma virus, may be used for delivery of the recited polynucleotides or vector into targeted cell populations.
- nucleic acid molecules and vectors can be reconstituted into liposomes for delivery to target cells.
- the vectors containing the nucleic acid molecules of the invention can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment or electroporation may be used for other cellular hosts; see Sambrook, supra.
- the recited vector may, inter alia, be the pEF-DHFR, pEF-ADA or pEF-neo.
- the vectors pEF-DHFR, pEF-ADA and pEF-neo have been described in the art, e.g. in Mack et al. (PNAS (1995) 92, 7021-7025) and Griffin et al. (Cancer Immunol Immunother (2001) 50(3), 141-150).
- the invention also provides for a host transformed or transfected with a vector as described herein.
- Said host may be produced by introducing said at least one of the above described vector or at least one of the above described nucleic acid molecules into the host.
- the presence of said at least one vector or at least one nucleic acid molecule in the host may mediate the expression of a gene encoding the above described bispecific single chain antibody constructs.
- the described nucleic acid molecule or vector which is introduced in the host may either integrate into the genome of the host or it may be maintained extrachromosomally.
- the host can be any prokaryotic or eukaryotic cell.
- Prokaryote is meant to include all bacteria which can be transformed or transfected with DNA or RNA molecules for the expression of a protein of the invention.
- Prokaryotic hosts may include gram negative as well as gram positive bacteria such as, for example, E. coli, S. typhimurium, Serratia marcescens and
- Bacillus subtilis Bacillus subtilis.
- the term "eukaryotic” is meant to include yeast, higher plant, insect and preferably mammalian cells.
- the protein encoded by the polynucleotide of the present invention may be glycosylated or may be non-glycosylated.
- the length of said FLAG-tag is about 4 to 8 amino acids, most preferably 8 amino acids.
- An above described polynucleotide can be used to transform or transfect the host using any of the techniques commonly known to those of ordinary skill in the art. Furthermore, methods for preparing fused, operably linked genes and expressing them in, e.g., mammalian cells and bacteria are well-known in the art (Sambrook, loc cit.).
- said the host is a bacteria, an insect, fungal, plant or animal cell.
- the recited host may be a mammalian cell, more preferably a human cell or human cell line.
- Particularly preferred host cells comprise CHO cells, COS cells, myeloma cell lines like SP2/0 or NS/0. As illustrated in the appended examples, particularly preferred are CHO-cells as hosts.
- the present invention thus relates to a process for the preparation of a CD3 specific construct described above comprising cultivating a cell and/or the host of the invention under conditions suitable for the expression of said construct and isolating the construct from the cell or the culture medium.
- the transformed hosts can be grown in fermentors and cultured according to techniques known in the art to achieve optimal cell growth.
- the polypeptide of the invention can then be isolated from the growth medium, cellular lysates, or cellular membrane fractions.
- isolation and purification of the, e.g., microbially expressed polypeptides of the invention may be by any conventional means such as, for example, preparative chromatographic separations and immunological separations such as those involving the use of monoclonal or polyclonal antibodies directed, e.g., against a tag of the polypeptide of the invention or as described in the appended examples.
- the invention provides for a composition
- a composition comprising a (human) CD3- specific binding construct as defined herein or a (human) CD3-specific binding construct as produced by the process disclosed above, a nucleic acid molecule of the invention, a vector or a host of the invention.
- Said composition may, optionally, also comprise a proteinaceous compound capable of providing an activation signal for immune effector cells.
- said composition is a pharmaceutical composition further comprising, optionally, suitable formulations of carrier, stabilizers and/or excipients.
- the term "pharmaceutical composition” relates to a composition for administration to a patient, preferably a human patient.
- the pharmaceutical composition comprises a composition for parenteral, transdermal, intraluminal, intra arterial, intrathecal administration or by direct injection into the tissue or tumour. It is in particular envisaged that said pharmaceutical composition is administered to a patient via infusion or injection. Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration.
- the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier.
- Suitable pharmaceutical carriers include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions, etc.
- Compositions comprising such carriers can be formulated by well known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently.
- the regimen as a regular administration of the pharmaceutical composition should be in the range of 1 ⁇ g to 5 g units per day.
- a more preferred dosage for continuous infusion might be in the range of 0.01 ⁇ g to 2 mg, preferably 0.01 ⁇ g to 1 mg, more preferably 0.01 ⁇ g to 100 ⁇ g, even more preferably 0.01 ⁇ g to 50 ⁇ g and most preferably 0.01 ⁇ g to 10 ⁇ g units per kilogram of body weight per hour.
- Particularly preferred dosages are recited herein below.
- Progress can be monitored by periodic assessment. Dosages will vary but a preferred dosage for intravenous administration of DNA is from approximately 10 6 to 10 12 copies of the DNA molecule.
- the compositions of the invention may be administered locally or systematically.
- Administration will generally be parenterally, e.g., intravenously; DNA may also be administered directed to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery.
- Preparations for parenteral administration include sterile aqueous or non- aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
- Intravenous vehicles include fluid and nutrient replenishes, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
- the pharmaceutical composition of the present invention might comprise proteinaceous carriers, like, e.g., serum albumine or immunoglobuline, preferably of human origin.
- the pharmaceutical composition of the invention might comprise, in addition to the proteinaceous bispecific single chain antibody constructs or nucleic acid molecules or vectors encoding the same (as described in this invention), further biologically active agents, depending on the intended use of the pharmaceutical composition.
- agents might be drugs acting on the gastro-intestinal system, drugs acting as cytostatica, drugs preventing hyperurikemia, drugs inhibiting immunereactions (e.g. corticosteroids), drugs acting on the circulatory system and/or agents such as T-cell co-stimulatory molecules or cytokines known in the art.
- tumorous diseases especially epithelial cancers/carcinomas such as breast cancer, colon cancer, prostate cancer, head and neck cancer, skin cancer (melanoma), cancers of the genito-urinary tract, e.g. ovarial cancer, endometrial cancer, cervix cancer and kidney cancer, lung cancer, gastric cancer, cancer of the small intestine, liver cancer, pancreas cancer, gall bladder cancer, cancers of the bile duct, esophagus cancer, cancer of the salivatory glands and cancer of the thyroid gland or other tumorous diseases like haematological tumors, gliomas, sarcomas or osteosarcomas.
- epithelial cancers/carcinomas such as breast cancer, colon cancer, prostate cancer, head and neck cancer, skin cancer (melanoma)
- cancers of the genito-urinary tract e.g. ovarial cancer, endometrial cancer, cervix cancer and kidney cancer
- lung cancer gastric cancer
- composition(s) of the invention is especially indicated for minimal residual disease, preferably early solid tumors, advanced solid tumors or metatatic solid tumors, which is characterized by the local and non-local reoccurrance of the tumor caused by the survival of single cells.
- the invention further envisages the co-administration protocols with other compounds, e.g. molecules capable of providing an activation signal for immune effector cells, for cell proliferation or for cell stimulation.
- Said molecule may be, e.g. a further primary activation signal for T cells (e.g. a further costimulatory molecule: molecules of B7 family, Ox40L, 4.1 BBL), or a further cytokine: interleukin (e.g. IL-2) or NKG-2D engaging compound.
- composition of the invention as described above may also be a diagnostic composition further comprising, optionally, means and methods for detection.
- the CD3-specific constructs provided herein are also suited for use in immunoassays in which they can be utilized in liquid phase or bound to a solid phase carrier.
- immunoassays which can utilize the polypeptide of the invention are competitive and non-competitive immunoassays in either a direct or indirect format.
- examples of such immunoassays are the enzyme linked immunosorbent assay (ELISA), enzyme immunoassay (EIA) , radioimmunoassay (RIA), the sandwich (immunometric assay) and the Western blot assay.
- the CD3 specific binding constructs of the invention can be bound to many different carriers and used to isolate cells specifically bound to said polypeptides.
- carriers include glass, polystyrene, polyvinyl chloride, polypropylene, polyethylene, polycarbonate, dextran, nylon, amyloses, natural and modified celluloses-, polyacrylamides, agaroses, and magnetite.
- the nature of the carrier can be either soluble or insoluble, e.g. as beads, for the purposes of the invention.
- labels there are many different labels and methods of labeling known to those of ordinary skill in the art.
- Examples of the types of labels which can be used in the present invention include enzymes, radioisotopes, colloidal metals, fluorescent compounds, chemiluminescent compounds, and bioluminescent compounds; see also the embodiments discussed hereinabove.
- a CD3 specific binding molecule of the invention of a vector or of a host of the invention for the preparation of a pharmaceutical composition
- Said pharmaceutical composition may be employed in the prevention, treatment or amelioration of a proliferative disease, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, viral disease, allergic reactions, parasitic reactions, graft-versus-host diseases or host-versus-graft diseases.
- the deimmunized constructs comprising CD19 and CD3 binding domains, preferably SEQ ID NO.:190, 192, 194, 196, 198, 200, 327, 329, 331 , 333, 335, 337, 339, 341 , 343, 345, 347, 349, 351 , 353, 357, 359, 361 , 363, 365, 367, 369, 371, 373, 375, 377, 379, 381 , 383, 385, 387, 389, 391 , 393, 395, 397, 399, 401 , 403, 405, 407 or 409, can be used for the treatment of immunological disorders (various B cell malignancies) or autoimmune diseases
- the deimmunized constructs comprising CCR5 and CD3 binding domains preferably SEQ ID NO.:206, 208, 210, 212, 214 or 216
- HIV viral diseases
- the invention also relates to a method for the prevention, treatment or amelioration of a proliferative disease, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, viral disease, allergic reactions, parasitic reactions, graft-versus-host diseases or host-versus-graft diseases comprising the administration of a (bispecific) CD3 specific binding molecule of the invention or a (bispecific) CD3 specific binding molecule as produced by the process described herein, of a nucleic acid molecule, a vector or a host of the invention to a subject in need of such a prevention, treatment or amelioration .
- said subject is a human.
- the method for the prevention, treatment or amelioration may also, in addition, comprise the administration of a proteinaceous compound capable of providing an activation signal for immune effector cells.
- Said proteinaceous compound may be administered simultaneously or non-simultaneously with the CD3 binding molecule, a nucleic acid molecule, a vector or a host of the invention.
- the proteinaceous compound may, inter alia, selected from the group consisting of a further costimulatory molecule:molecules of B7 family, Ox40L, 4.1 BBL), or a further cytokine: interleukin (e.g. IL-2) or NKG-2D engaging compounds.
- the invention provides for a kit comprising the CD3 specific binding molecule, a nucleic acid molecule, a vector or a host of the invention.
- kits are particularly useful in the preparation of the pharmaceutical composition of the present invention and may, inter alia, consist of a container useful for injections or infusions.
- the kit of the present invention further comprises, optionally (a) buffer(s), storage solutions and/or remaining reagents or materials required for the conduct of medical or scientific purposes.
- parts of the kit of the invention can be packaged individually in vials or bottles or in combination in containers or multicontainer units.
- the kit of the present invention may be advantageously used, inter alia, for carrying out the method of the invention and could be employed in a variety of applications referred herein, e.g., as research tools or medical tools.
- the manufacture of the kits preferably follows standard procedures which are known to the person skilled in the art.
- Figure 1 DNA and amino acid sequences of the non-deimmunized anti-CD3 cassette (SEQ ID NOs.: 1 and 2).
- FIG. 1 Amino acid sequences of the heavy chains VH2 (SEQ ID NO.:70), VH3 (SEQ ID NO.:72), VH5 (SEQ ID NO.:74) and VH7 (SEQ ID NO.:76) and light chains VL1 (SEQ ID NO.:78), VL2 (SEQ ID NO.:80) and VL3 (SEQ ID NO.:82), respectively
- Figure 3 A) Nucleotide sequence of anti-CD3 (VH2/VL1) (SEQ ID NO.:4) B) Amino acid sequence of anti-CD3 (VH2/VL1) (SEQ ID NO.:5) C) Nucleotide sequence of anti-CD3 (VH2/VL2) (SEQ ID NO.:6) D) Amino acid sequence of anti-CD3 (VH2/VL2) (SEQ ID NO.:7) E) Nucleotide sequence of anti-CD3 (VH2/VL3) (SEQ ID NO.:8) F) Amino acid sequence of anti-CD3 (VH2/VL3) (SEQ ID NO.:9).
- FIG. 1 Nucleotide sequence of anti-CD3 (VH5/VL1) (SEQ ID NO.: 16)
- B Amino acid sequence of anti-CD3 (VH5/VL1) (SEQ ID NO.: 17)
- E Nucleotide sequence of anti-CD3 (VH5/VL3) (SEQ ID NO.:20)
- F Amino acid sequence of anti-CD3 (VH5/VL3) (SEQ ID NO.:21).
- FIG. 6 A) Nucleotide sequence of anti-CD3 (VH7/VL1) (SEQ ID NO.:22) B) Amino acid sequence of anti-CD3 (VH7xVL1) (SEQ ID NO.:23) C) Nucleotide sequence of anti-CD3 (VH7/VL2) (SEQ ID NO.:24) D) Amino acid sequence of anti-CD3 (VH7xVL2) (SEQ ID NO.:25) E) Nucleotide sequence of anti-CD3 (VH7/VL3) (SEQ ID NO.:26) F) Amino acid sequence of anti-CD3 (VH7/VL3) (SEQ ID NO.:27).
- FIG. 7 Binding of bispecific anti-CD19 constructs with different deimmunized anti- CD3 parts: the anti-CD3 (VH2/VL1) (SEQ ID NO.:178), anti-CD3 (VH2/VL2) (SEQ ID NO.:180), anti-CD3 (VH2/VL3) (SEQ ID NO.:182), anti-CD3 (VH3/VL1) (SEQ ID NO.:184), anti-CD3 (VH3/VL2) (SEQ ID NO.:186), anti-CD3 (VH3/VL3) (SEQ ID NO.:188), anti-CD3 (VH5/VL1) (SEQ ID NO.:190), anti-CD3 (VH5/VK2) (SEQ ID NO.: 192), anti-CD3 (VH5/VL3) (SEQ ID NO.: 194), anti-CD3 (VH7/VL1) (SEQ ID NO.:196), anti-CD3 (VH7/VL2) (SEQ ID NO.
- Binding was measured by a FACS-based assay using CD3 enriched PBMCs (A) or CD19-positive NALM-cells (B).
- CD3 and a secondary FITC labeled anti-mouse Ig antibody was used as a negative control in (A) and CD19 and a secondary FITC labeled anti-mouse Ig antibody was used as a negative control in (B).
- Constructs anti-CD 19xanti-CD3 and anti-EpCAM (M79)xanti- CD3 were used as controls.
- MFI indicates mean fluorescence intensity.
- Figure 8 A representative elution pattern of a deimmunized variant of anti- CD 19xanti-CD3 protein fraction from a HCIC column at 280 nm.
- the bottom line showing a major step at 700 ml indicates the theoretical gradient of the elution buffer containing 20 mM acetate, pH3.5. High adsorption at 280 nm was due to non-bound protein in the column flow-through.
- the arrow at 810,98 ml indicates the eluted deimmunized anti-CD3 fraction.
- Figure 9 A representative elution pattern of a deimmunized variant of anti- CD 19xanti-CD3 protein fraction from a Ni-Chelating His Trap® column at 280 nm.
- the bottom line showing a first step at 85 ml and a second major step at 90 ml indicates the theoretical gradient of the elution buffer (dotted line).
- the arrow at 93,16 ml indicates the protein fraction containing the antiCD19 x antiCD3 construct.
- Figure 10 A representative protein elution pattern from a Sephadex S200 gelfiltration column. Fractions were collected from 0-130 ml retention time. The protein peak at 80.44 ml corresponds to a MW of ca. 52 kD and contains the deimmunized antiCD19 x antiCD3 construct.
- Figure 11 A) SDS-PAGE analysis of deimmunized variants of anti-CD 19xanti-CD3 protein fractions.
- Lane M Molecular weight marker
- Lane 1 HCIC flowthrough
- lane 2 cell culture supernatant
- lane 3 HCIC eluate
- lane 4 IMAC flowthrough
- lane 5 IMAC wash
- lane 6 IMAC eluate
- lane 7 gel filtration eluate
- FIG. 12 Binding of the purified bispecific anti-CD19 constructs with different deimmunized anti-CD3 parts: anti-CD3 (VH5/VL1) (SEQ ID NO.: 190), anti-CD3 (VH7/VL1) (SEQ ID NO.:196), anti-CD3 (VH7/VL2) (SEQ ID NO.:198) and anti-CD3 (VH7/VL3) (SEQ ID NO.:200) to A) CD3 and B) CD19 compared to the wild-type anti- CD 19xanti-CD3 construct. Binding was measured by a FACS-based assay using CD3 enriched PBMCs (A) or CD19-positive NALM-cells (B).
- a secondary antibody with CD3 positive cells was used as a negative control in (A) and a secondary antibody with CD 19 positive cells was used as a negative control in (B).
- Constructs anti-CD19xanti-CD3 and anti-EpCAM (M79)xanti-CD3 were used as controls.
- Assay was carried out with concentrations of 1 ⁇ g/ml and 5 ⁇ g/ml. MFI indicates mean fluorescence intensity.
- FIG. 14 Sequence alignment of variable heavy region of the non-deimmunized CD3 antibody, VH5 (SEQ ID NO.:74), VH7 (SEQ ID NO.:76), VH2 (SEQ ID NO.:70) and VH3 (SEQ ID NO.:72).
- Framework region 1 (FR1), complementarity determining region 1 (CDR1), Framework region 1 (FR1), complementarity determining region 2 (CDR2), Framework region 3 (FR3), complementarity determining region 3 (CDR3) and Framework region 4 (FR4) have been depicted.
- sequence LAR and VKK in FR1 the sequence ASGYTF and ASGYTA at the transition of framework 1 region to CDR1 region and the sequence LTTDK, ITTDK and MTTDT at FR3 and the sequence MQLS, MELS and LQMN at FR3 have been boxed. Alignment was carried out using the AlingnX program of Vector NTI Advance (Informax, Inc., USA).
- FIG. 15 Binding analysis of bispecific anti EpCAM constructs with different deimmunized anti-CD3 parts: anti-CD3 (VH5/VL2)x5-10 (SEQ ID NO.:37) (A), deimmunized anti-CD3 (VH5/VL2)x4-7 (SEQ ID NO.:33), (B) deimmunized anti-CD3 (VH5/VL2)x3-1 (SEQ ID NO.:31) (C), deimmunized anti-CD3 (VH5/VL2)x4-7 (VL-VH) (SEQ ID NO.:35) (D) and deimmunized anti-CD3 (VH5/VL2)x5-10 (VL-VH) (SEQ ID NO.:39) (E) in CD3-positive Jurkat and EpCAM-positive Kato III cells with a FACS- based assay.
- FIG. 17 Cytotoxicity assay of EpCAM constructs with deimmunized anti-CD3 parts (di anti-CD3) at N-terminal position anti-CD3 (VH5/VL2)x3-1 (SEQ ID NO.:31), anti- CD3 (VH5/VL2)x-5-10 (SEQ ID NO.:37) and anti-CD3 (VH5/VL2)x4-7 (SEQ ID NO.:33) compared to the corresponding non-deimmunized constructs.
- CB15 T cell clone and CHO-EpCAM cells were used in an E:T ratio of 5:1.
- CHO-EpCAM cell were stained with PKH26 dye and the cells were counted after bispecific single chain antibody incubation with FACS analysis.
- the different deimmunized anti-human CD3 antibodies comprise 12 combinations of 4 different VH (VH2 (SEQ ID NO.:69, 70), VH3 (SEQ ID NO.:71 , 72), VH5 (SEQ ID N0..73, 74) and VH7 (SEQ ID NO.:75, 76)) and 3 different VL (VL1 (SEQ ID NO.:77, 78), VL2 (SEQ ID NO.:79, 80) and VL3 (SEQ ID NO.:81 , 82)) regions joined together.
- VH2 SEQ ID NO.:69, 70
- VH3 SEQ ID NO.:71 , 72
- VH5 SEQ ID N0..73, 74
- VH7 SEQ ID NO.:75, 76
- VL1 VL1
- VL2 SEQ ID NO.:79, 80
- VL3 SEQ ID NO.:81 , 82
- the DNA encoding the anti-CD3 single-chain antibody, which was deimmunized, is referred herein as the anti-CD3 cassette.
- This anti-CD3 cassette consists of a SGGGGS linker (SEQ ID NO.:176), the anti-CD3 VH region (SEQ ID NO.:1 10), a 14 amino acid GS linker (VEGGSGGSGGSGGSGGVD linker (SEQ ID NO.:68)), and the anti-CD3 VL chains region (SEQ ID NO.:112) followed by 6 histidine residues.
- the afore-mentioned DNA was cloned into the vector p-PCR-Script-Amp SK(+) (Stratagene) at the Srf1 site.
- the DNA and amino acid sequence of the anti-CD3 cassette is shown in SEQ ID NO.:1 , SEQ ID NO.:2 and Figure 1.
- SEQ ID NO.2 The amino acid sequence of the anti-CD3 cassette (SEQ ID NO.:2) was analyzed by peptide threading program to identify potential T cell epitopes with the method as described in WO 98/52976.
- SEQ ID NO.3 shows the deimmunized linker sequence and SEQ ID NO.:68 the original linker sequence.
- the deimmunized versions of the anti-CD3 cassette were constructed by the method of overlapping PCR recombination.
- the anti-CD3 cassette (SEQ ID NO.:1 , 2) in pPCR-S-Amp SK+ was used as the template for mutagenesis to the required deimmunized sequences.
- Sets of mutagenic primer pairs were synthezised encompassing the regions to be altered.
- VH and 3 different VK regions were joined in all combinations (a total of 12), either by PCR or using a unique BstE11 site introduced at the 3' end of the VH region.
- the entire DNA sequence of each combination was confirmed to be correct.
- the different deimmunized VH regions (SEQ ID NO.:70, 72, 74 and 76) and VL regions (SEQ ID NO.:78, 80 and 82) with the corresponding original non-deimmunized sequences (VH:SEQ ID NO.:110; VL:SEQ ID NO.:112) of the anti-CD3 constructs are summarized in Table 9.
- the deimmunized anti-CD3 cassettes were excised from pPCR-S-Amp-SK+ with BspEI and Sail and cloned into the expression vector pEF comprising VL CDI9 - VHCDI 9 -VHCD 3 -VLCD3-
- the CD3 part of the pEF-DHFR vector was replaced with each of the deimmunized anti-CD3 cassettes from the BspEI site to the Sail site resulting in the following 12 constructs:
- pEF anti CD19xanti ⁇ CD3 (VH2/VL1) (SEQ ID NOs. 177, 178) pEF anti CD19xanti ⁇ CD3 (VH2/VL2) (SEQ ID NOs. 179, 180) pEF anti CD19xanti ⁇ CD3 (VH2/VL3) (SEQ ID NOs. 181 , 182) pEF anti CD19xanti • CD3 (VH3/VL1) (SEQ ID NOs. 183, 184) pEF anti CD19xanti -CD3 (VH3/VL2) (SEQ ID NOs. 185, 186) pEF anti CD19xanti ⁇ CD3 (VH3/VL3) (SEQ ID NOs.
- the constructs further comprises a murine IgG heavy chain leader in order to enable the secretion ot the protein.
- the DNA sequences of the deimmunized anti-CD3 cassettes in the expression vector were confirmed using the sequencing primers (SEQ ID NO.: 28 and 29).
- the DNA and amino acid sequences of the 12 deimmunized anti-CD3 cassettes in the pEF vector from the BspEI site to the Sail site are shown in SEQ ID NOs.: 177-200.
- transfection-grade DNAs of the different expression vectors were prepared.
- Secreted proteins were produced in CHO-dhfr- cells.
- the cell culture supernatants were harvested 2 days after transfection, for the generation of stable transfected cells, cells were put in selection medium two days after transfection. After five passages, stable pools were obtained. Subsequently, single clones were identified in limiting dilutions. To facilitate the purification process, the cells were adapted to serum-free medium.
- Antibody constructs were purified from about 1 liter of supernatant. The production levels were tested in ELISA. No major differences in the secreted antibody levels were observed between different constructs comprising anti-CD 19 and deimmunized anti-CD3 constructs.
- a FACS-based assay was performed. Initially, crude supernatants were tested for binding on CD3-enriched PBMCs or CD19-positive NALM-6 cells. Cells were incubated with non-diluted supernatants for 30 minutes at 8 °C. Upon two wash steps the cells were labeled with an anti-His antibody (Qiagen) under the same conditions. After additional wash steps binding of the constructs was detected with a FITC- conjugated sheep anti-mouse antibody (Sigma). Cells were analyzed with a FACS Calibur cytometer (B&D).
- anti-CD 19xanti-CD3 constructs comprising anti-CD3 (VH5/VL1) (SEQ ID NO.: 190), anti-CD3 (VH5/VL2) (SEQ ID NO.:192), anti-CD3 (VH5/VL3) (SEQ ID NO.:194), anti- CD3 (VH7/VL1) (SEQ ID NO.:196), anti-CD3 (VH7/VL2) (SEQ ID NO.:198) and anti- CD3 (VH7/VL3) (SEQ ID NO.:200) had a MFI of at least 90, thus binding about 25 times more strongly.
- the positive control which was a non-deimmunized anti- CD19xanti-CD3 construct reached a MFI of around 60 showing that the deimmunized constructs comprising anti-CD3 (VH5/VL1) (SEQ ID NO.: 190), anti-CD3 (VH5/VL2) (SEQ ID NO.:192), anti-CD3 (VH5/VL3) (SEQ ID NO.:194), anti-CD3 (VH7/VL1) (SEQ ID NO..-196), anti-CD3 (VH7/VL2) (SEQ ID NO.:198) and anti-CD3 (VH7/VL3) (SEQ ID NO.:200) bound CD3 with extremely high efficacy.
- anti-CD3 VH2/VL1
- anti-CD3 VH2/VL2
- anti-CD3 VH2/VL3
- anti-CD3 VH2/VL3
- anti-CD3 VH3/VL1
- anti-CD3 VH3/VL2
- anti-CD3 VH3/VL2
- anti-CD3 VH3/VL2
- anti-CD3 VH3/VL2
- anti-CD3 VH3/VL3
- VH3/VL3 VH3/VL3
- anti-CD3 VH3/VL3
- VH3/VL3 VH3/VL3
- SEQ ID NO.: 188 showed similar binding as the negative control (MFI ca. 6).
- the FACS-based binding assay was also carried out for CD19.
- CD19 and a secondary antibody was as a negative control.
- all assayed constructs achieved a MFI of at least 80 while the MFI of the negative control was ca. 3.
- the constructs comprising anti-CD3 (VH5/VL1) (SEQ ID NO.: 190), anti-CD3 (VH5/VL2) (SEQ ID NO.:192), anti-CD3 (VH5/VL3) (SEQ ID NO.:194), anti-CD3 (VH7/VL1) (SEQ ID NO.:196), anti-CD3 (VH7/VL2) (SEQ ID NO.:198) and anti-CD3 (VH7/VL3) (SEQ ID NO.:200) turned out to bind as well CD3 and CD19 as the non- modified anti-CD19xanti-CD3 (SEQ ID NO.:204).
- anti-CD3 VH2/VL1
- anti-CD3 VH2/VL2
- anti-CD3 VH2/VL3
- anti-CD3 VH3/VL1
- anti-CD3 VH3/VL2
- anti-CD3 VH3/VL2
- anti-CD3 VH3/VL3
- anti-CD3 VH3/VL3
- anti-CD3 VH5/VL2
- anti-CD3 VH5/VL3
- anti-CD3 VH5/VL3
- anti-CD3 VH7/VL1
- anti-CD3 VH7/VL2
- anti-CD3 VH7/VL2
- CHO-CD19 cells were grown in roller bottles with HiClone CHO modified DMEM medium (HiQ)® for 7 days before harvest. The cells were removed by centrifugation and the supernatant, containing the expressed protein was stored at
- Akta FPLC System® (Pharmacia) and Unicorn Software® were used for chromatography. All chemicals were of research grade and purchased from Sigma
- IMAC was performed, using a HisTrap® column (Pharmacia) that was loaded with
- the column was equilibrated with buffer A2 (20 mM NaP pH 7.5, 0.4 M NaCI) and the sample was diluted 2:1 with buffer A2 to obtain a pH of 7.
- the sample was applied to the column (2 ml) with a flow rate of 1 ml/min and the column was washed with buffer A2 to remove unbound sample.
- Bound protein was eluted using a 2 step gradient of buffer B2 (20 mM NaP pH 7.5, 0.4 M NaCI, 0.5 M Imidazol) Step 1 : 20% buffer B2 in 10 column volumes;
- Step 2 100% buffer B2 in 10 column volumes. Eluted protein fractions were pooled for further purification.
- the deimmunized variants of anti-CD 19xanti-CD3 protein were isolated in a three step purification process including hydrophobic charge induction chromatography (HCIC) ( Figure 8), immobilized metal affinity chromatography (IMAC) ( Figure 9) and gel filtration ( Figure 10).
- the bispecific construct had a molecular weight of 52 kDa under native conditions as determined by gelfiltration in PBS.
- the purified bispecific protein was analyzed with SDS-PAGE under reducing conditions using precast 4-12% Bis Tris gels (Invitrogen). Sample preparation and application were according to the manufacturer's protocol. The molecular weight was determined with MultiMark® protein standard (Invitrogen). The gel was stained with colloidal Coomassie (Invitrogen protocol). The purity of the isolated protein was >95% ( Figure 11a) and the molecule has a size of 52 kD.
- the deimmunized variants of anti-CD19xanti-CD3 protein were specifically detected by Western Blot.
- Western Blot was performed with an Optitran BA-S83® membrane and the Invitrogen Blot Module® according to the manufacturer's protocol.
- the antibodies used were Penta His (Quiagen) and Goat-anti-Mouse-lg labeled with alkaline phophatase (AP) (Sigma), the staining solution was BCIP/NBT liquid (Sigma).
- the main signal was shown to correspond to the main band in the SDS-PAGE at 52kD ( Figure 11 b).
- Protein concentrations were determined using protein assay dye (MicroBCA®, Pierce) and IgG (Biorad) as standard protein.
- a summary of the final yields of purified protein variants is given in Table 10 showing the high productivity of all the constructs and very good yield of construct with anti-CD3 (VH5/VL1) (SEQ ID NO.: 190) of 924.8 ⁇ g-
- Table 11 clearly demonstrates that the bispecific constructs comprising deimmunized CD3 binding domain have much higher (at least three fold) productivity than the corresponding non-deimmunized construct.
- Binding of selected purified antibody constructs comprising anti-CD19 and anti-CD3 was detected as described above in Example 2 at various concentrations.
- the negative control secondary antibody anti-His, FITC-conjugated
- CD3 positive cells showed a MFI of about 2.5
- the positive control deimmunized antiCD19xanti-CD3 bispecific single chain antibody of about 70 at 1 ⁇ g/ml concentration and 50 at 5 ⁇ g/ml concentration ( Figure 12A).
- the anti-CD3 (VH5/VL1) SEQ ID NO.:190
- anti-CD3 VH7/VL1
- anti-CD3 VH7/VL2
- anti-CD3 VH7/VL2
- anti-CD3 VH7/VL3
- anti-CD3 VH7/VL3
- anti-CD3 VH7/VL2
- SEQ ID NO.:198 reached a MFI of 25
- anti-CD3 VH7/VL1
- anti-CD3 VH7/VL3
- anti-CD3 VH5/VL1
- SEQ ID NO.:190 had an MFI of at least 40 thus, showing the same binding efficacy than the non-deimmunized positive control.
- the strongly binding constructs with deimmunized anti-CD3 part VH5/VL1 (SEQ ID NO.:190), VH7/VL1 (SEQ ID NO.:196), VH7/VL2 (SEQ ID NO.:198), VH7/VL3 (SEQ ID NO.:200) bound to CD3 as well as the non-deimmunized anti-CD 19xanti- CD3 (SEQ ID NO.:204).
- Anti-CD19xanti-CD3 mediates T cell dependent cytotoxicity to CD19-positive target cells. This was analyzed in vitro for the determination of the biological potency of anti-CD 19xanti-CD3.
- fluorescence labeled CD19-positive NALM-6 target cells were incubated with isolated PBMC of random donors or CB15 T-cells (standardized T-cell line) as effector cells in the presence of anti-CD 19xanti-CD3. After incubation for 4 h at 37 °C in a humidified incubator, the release of the fluorescent dye from the target cells into the supernatant is determined in a spectrofluorimeter.
- Target cells incubated without anti-CD 19xanti-CD3 and target cells totally lysed by the addition of saponin at the end of the incubation serve as negative and positive controls, respectively.
- the specific cytotoxicity mediated at a certain anti-CD 19xanti-CD3 concentration can be calculated with the following formula:
- the dose response was analyzed from 0.4 pg/ml anti-CD 19xanti-CD3 to 100 ng/ml anti-CD 19xanti-CD3 to specify the EC50 value.
- the EC50 value describes the biological potency of anti-CD19xanti-CD3, the absolute value will vary significantly depending on the source of the effector cells.
- the cytotoxic activities of the constructs comprising anti-CD19 and deimmunized anti-CD3 are shown in Figure 13.
- Purified non-deimmunized anti-CD 19xanti-CD3 was used as control.
- the EC50 values of the deimmunized constructs were at a range of 21.9-81.6 pg/ml while the EC50 value of the non-deimmunized anti-
- CD19xanti-CD3 construct was 22.7 pg/ml. Thus, all deimmunized constructs revealed EC 50 values comparable to the non-deimmunized molecule.
- Example 6 T-cell proliferation assay
- Table 12 HLA DR haplotypes of 20 healthy donors used to test the immunogenicity of peptides obtained from deimmunized and non-deimmunized anti-CD3 scAb.
- Peptides were obtained from Pepscan (Netherlands) at a purity of greater than 90%.
- Peripheral blood mononuclear cells (PBMC) from the 20 selected healthy donors (Table 12) were used to screen individual peptides in triplicate wells at 1 and 5 ⁇ M.
- an 18 hour pulse with 3H-thymidine at 1 ⁇ Ci/well was used to assess T cell proliferation.
- a T cell epitope is defined as a peptide giving a stimulation index (SI) greater than 2.
- SI stimulation index
- Table 13 summarizes the T cell proliferation assay results showing Mean SI values of 2 independent runs. The data also showed a concentration dependent effect whereby each of the non- deimmunized binding molecules showed Si's > 2 in only one of the two concentrations (1 ⁇ m or 5 ⁇ m) used.
- Table 13 Summary of data comparing positive (Sl>2) mouse peptides and corresponding deimmunized peptides.
- Example 7 Homology alignment of anti-CD3 (VH5), anti-CD3 (VH7), anti-CD3 (VH2) and anti-CD3 (VH3) with the non-deimmunized anti-CD3 VH
- variable heavy region of the non-deimmunized CD3 antibody VH5 (SEQ ID NO.:74), VH7 (SEQ ID NO.:76), VH2 (SEQ ID NO.:70) and VH3 (SEQ ID NO.:72) were aligned using the AlingnX program of Vector NTI Advance (Informax, Inc., USA).
- the Clustal W algorithm used is described in Nucleic Acid Research, 22 (22): 4673-4860, 1994.
- the alignment is shown in Figure 14. From the alignment can be seen that the variable regions VH5 and VH7, which show surprisingly good binding have the sequence ASGYTF at the transition region of framework 1 to CDR1.
- VH regions showing no binding comprise the sequence ASGYTA at the transition of framework 1 to CDR1.
- the construct has to comprise the sequence ASGYTF at the transition of framework 1 to CDR1.
- the variable heavy regions binding to CD3 and showing reduced propensity to generate T cell epitopes comprising the above-mentioned sequence ASGYTF show good binding.
- Example 8 Cloning of constructs comprising deimmunized anti-CD3 and anti- EpCAM
- deimmunized anti-CD3 polypeptide of the invention can be a part of a functional construct with other targets, a number of bispecific constructs comprising deimmunized anti-CD3 (VH5/VL2) (SEQ ID NO.: 19) and different anti-EpCAM single chain antibodies (3-1 (SEQ ID NO.: 137, 139), 3-5 (SEQ ID NO.:141 , 143), 4-1 (SEQ ID NO.:145, 147), 4-7 (SEQ ID NO.:149, 151), 5-10 (SEQ ID NO.:133, 135)) were generated.
- VH5/VL2 deimmunized anti-CD3
- VH5/VL2 deimmunized anti-CD3
- different anti-EpCAM single chain antibodies 3-1 (SEQ ID NO.: 137, 139), 3-5 (SEQ ID NO.:141 , 143), 4-1 (SEQ ID NO.:145, 147), 4-7 (SEQ ID NO.:149, 151
- the above mentioned PCR product containing the deimmunized anti-CD3 was cleaved with the restriction enzymes BsrGI and BspEI and subsequently cloned into the bluescript KS vector (Stratagene, La Jolla, CA), containing the amino acid sequence of an eukaryotic secretory signal (leader peptide) as a EcoRI/BsrGI- fragment.
- Anti-EpCAM 4-7 in VL-VH orientation containing the 15 amino acid standard linker (SEQ ID NO.: 168) was obtained by PCR.
- the 4-7 VH region and the 4-7 VL region were separately amplified by the following primers (4-7 VL: 4-7 VL BspEI FOR CTGAAATCCGGAGGTGGTGGATCCGAGCTCGTGATGACCCAGACTCC (SEQ ID NO.:117), 4-7 VL GS15 REV GGAGCCGCCGCCGCCAGAACCACCA CCACCTTTGATCTCAAGCTTGGTCCCC (SEQ ID NO.:118); 4-7 VH: 4-7 VH GS15 FOR
- Anti-EpCAM 5-10 in VL-VH orientation containing the 15 amino acid standard ((G S ⁇ )3) linker was obtained by PCR.
- the 5-10 VH region and the 5-10 VL region were separately amplified by the following primers (5-10 VL: 5-10 VL BspEI FOR CTGAAATCCGGAGGTGGTGGATCCGAGCTCGTGATGACACAGTCTCCAT (SEQ ID N0..44), 5-10 VL GS15 REV
- TTTTAAGTCGACCTAATGATGATGATGATGATGTGAGGACGGTGACCGTGG SEQ ID NO.:47.
- Overlapping complementary sequences introduced into the PCR products were used to form the coding sequence of a 15-amino acid (G 4 S- ⁇ ) 3 (single- letter amino acid code) linker (standard linker) (SEQ ID NO.: 168) during the subsequent fusion PCR.
- This amplification step was performed with the primer pair 5-10 VL BspEI FOR and 5-10 VH Sail REV.
- the PCR products 5-10 VL-VH and 4-7 VL-VH) were cloned into the pEF-DHFR vector comprising anti-CD3 construct (VH5/VL2). After confirmation of the sequence coding for the bispecific single chain by sequencing the plasmid was transfected into DHFR deficient CHO cells for eukaryotic expression. Eukaryotic protein expression in DHFR deficient CHO cells was performed as described in Kaufmann R.J. (1990) Methods Enzymol. 185, 537-566).
- Deimmunized construct 3-1xanti-CD3 (VH5/VL2) (SEQ ID NO.: 48) was derived from non-deimmunized construct anti-EpCAM (3-1)xanti-CD3.
- the VH and VL regions of the anti-EpCAM antibody 3-1 are shown in SEQ ID NO.: 137 and 139.
- the plasmids pEF-DHFR-3-1x anti-CD3 and pEF anti-CD3 (VH5/VL2) (SEQ ID NO.:192) were digested with BspEI and Sail (Biolabs) for the isolation of the vector and the insert anti-CD3 (VH5/VL2), respectively.
- the BspEI-Sall-digested vector was dephosphorylated and purified on 0.7% agarose gel, whereas the insert was purified on 1.5% agarose gel.
- the C-terminal 3-1 in VH-VL orientation was obtained by PCR for the construction of non-deimmunized 3-1 x anti-CD3 molecule. Fragments I and II comprising the 3-1 VH-VL in two parts were amplified by PCR using primer pairs me 91a (SEQ ID NO.: 53) /me 90 (SEQ ID NO.: 52) and me 83 (SEQ ID NO.: 50) /me 84 (SEQ ID NO.: 51), respectively.
- Hot Start PCR was done using the Expand High Fidelity System of Roche Diagnostics. 20 cycles (94°C/30 sec; 60°C/1min;72°C/1min) were used for amplification followed by one cycle of 3 min at 72°C.
- PCR fragments I and II were subjected to electrophoresis on a 1.5% agarose gel. Fragments were mixed (1 ng of each) and used as a template for the next PCR reaction performed with primer pair me 91a (SEQ ID NO.: 53) and me 84 (SEQ ID NO.: 51) for amplification of fragment III comprising the entire 3-1. PCR was performed as described above, but with an annealing temperature of 68°C. Fragment III was purified on an agarose gel and digested with BsrGI and BspEI (Biolabs), purified and subsequently cloned into the corresponding sites of the pEF-DHFR-anti EpCAM (M79) X anti-CD3 construct. The cloned region was verified by restriction digests and by DNA-sequencing. Sequences of the Primers used:
- Me 84 5'- GTG CTC CGG AGG AGA CGG TGA CCG TGG TCC CTT GGC CCC
- Me 90 5'- CCG GAG CCG CCG CCA GAA CCA CCA CCA CCT TTG ATC
- Me 91a 5'- GGA TTG TAC A CTCC GA GCT CGT CAT GAC CCA GTC TCC ATC
- the C-terminal 3-5 in VH-VL orientation was obtained by PCR for the construction of 3-5 xanti-CD3 molecule.
- the VH and VL regions of the anti-EpCAM antibody 3-5 are shown in SEQ ID NO.:141 and 143.
- the plasmids pEF-DHFR-3-5xanti-CD3 and pEF anti-CD3 (VH5/VL2) (SEQ ID NO.: 192) were digested with EcoRI and BspEI (Biolabs) for the isolation of the insert (3-5) and the vector respectively.
- the dephosphorylated vector (EcoRI and BspEI digested) and the insert were purified by agarose gel-electrophoresis.
- the purified fragment (EcoRI-BspEI) was subsequently cloned into the corresponding sites of the pEF-DHFR vector.
- the final 3-5xanti-CD3 (VH5/VL2) (SEQ ID NO.:54) construct was verified by restriction digests.
- Fragments I and II comprising the 3-5 in two parts were amplified by PCR according to the conditions described for 3-1xanti-CD3 using primer pairs me 81 (SEQ ID NO.: 56) /me 90 (SEQ ID NO.: 52) and me 83 (SEQ ID NO.: 50) /me 84 (SEQ ID NO.: 51) respectively.
- Agarose gel fragments comprising PCR fragments I and II were reamplified with primer pair me 81 (SEQ ID NO.: 56) and me 84 (SEQ ID NO.: 51) for amplification of fragment III comprising the entire 3-5. PCR was performed as described above.
- Fragment III was purified on an agarose gel and digested with BssHII and BspEI (Biolabs), purified and subsequently cloned into the corresponding sites of the pEF-DHFRcloning vector. The cloned region was verified by restriction digests and by DNA-sequencing.
- the C-terminal 4-1 in VH-VL orientation was obtained by PCR for the construction of 4-1xanti-CD3 molecule.
- the VH and VL regions of the anti-EpCAM antibody 4-1 are shown in SEQ ID NO.:145 and 147.
- the plasmids pEF-DHFR-4-1xanti-CD3 and pEF anti-CD3 (VH5/VL2) (SEQ ID NO.: 192) were digested with EcoRI and BspEI (Biolabs) for the isolation of the insert (4-1) and the vector respectively.
- the dephosphorylated vector (EcoRI and BspEI digested) and the insert were purified by agarose gel-electrophoresis.
- the purified fragment (EcoRI-BspEI) was subsequently cloned into the corresponding sites of the vector.
- the final construct 4-1xanti-CD3 (VH5/VL2) (SEQ ID NO.:57) was verified by restriction digests.
- Fragments I and II comprising the 4-1 in two parts were amplified by PCR using primer pairs me 91a (SEQ ID NO.: 53) /me 90 (SEQ ID NO.: 452) and me 83 (SEQ ID NO.: 50) /me 84 (SEQ ID NO.: 51) with the above-mentioned conditions, respectively.
- Agarose gel fragments comprising PCR fragments I and II were reamplified with primer pair me 92a (SEQ ID NO.: 59) and me 84 (SEQ ID NO.: 51) for amplification of fragment III comprising the entire 4-1.
- PCR was performed as described above but annealing was performed at 68°C.
- Fragment III was purified on an agarose gel and digested with BsrGI and BspEI (Biolabs), purified and subsequently cloned into the corresponding sites of the pEF-DHFR-anti EpCAM (M79) X anti-CD3 cloning vector construct. The cloned region was verified by restriction digests and by DNA- sequencing. Sequence of the Me92a primer (SEQ ID NO.: 59):
- the C-terminal 4-7 in VH-VL orientation was obtained by PCR for the construction of 4-7 xanti-CD3.
- the VH and VL regions of the anti-EpCAM antibody 4-7 are shown in SEQ ID NO.:149 and 151.
- the plasmids pEF-DHFR-4-7xanti-CD3 and pEF anti-CD3 VH5/VL2 (SEQ ID NO.: 192) were digested with EcoRI and BspEI (Biolabs) for the isolation of the insert (4-7) and the vector respectively.
- the de-phosphorylated vector (EcoRI and BspEI digested) and the insert were purified by agarose gel- electrophoresis.
- the purified fragment (EcoRI-BspEI) was subsequently cloned into the corresponding sites of the pEF-DHFR vector.
- the final construct 4-7xanti-CD3 (VH5/VL2) (SEQ ID NO.:60) was verified by restriction digests.
- Fragments I and II comprising the 4-7 in two parts were amplified by PCR using primer pairs me 81 (SEQ ID NO.-.56) /me 90 (SEQ ID NO.:52) and me 83 (SEQ ID NO.:50) /me 84 (SEQ ID NO.:51) with the afore mentioned conditions, respectively.
- Agarose gel fragments comprising PCR fragments I and II were reamplified with primer pair me 81 (Seq ID NO.:56) and me 84 (Seq ID NO.:51) for amplification of fragment III comprising the entire 4-7 VH and VL chain. PCR was performed as described above.
- Fragment III was purified on an agarose gel and digested with BssHII and BspEI (Biolabs), purified and subsequently cloned into the corresponding sites of the pEF-DHFR cloning vector. The cloned region was verified by restriction digests and by DNA-sequencing.
- the purified fragment (EcoRI-BspEI) was subsequently cloned into the corresponding sites of the pEF-DHFR vector.
- the final construct 5-10xanti-CD3 (VH5/VL2) (SEQ ID NO.: 62) was verified by restriction digests and by DNA sequencing.
- Fragments I and II comprising the 5-10 in two parts were amplified by PCR using primer pairs me 92a (SEQ ID NO.: 59) /me 90 (SEQ ID NO.: 52) and me 83 (SEQ ID NO.: 50) /me 84 (SEQ ID NO.: 51) with the above mentioned conditions, respectively.
- Agarose gel fragments comprising PCR fragments I and II were reamplified with primer pair me 92a SEQ ID NO.: 59) and me 84 (SEQ ID NO.: 51) for amplification of fragment III comprising the entire 5-10. PCR was performed as described above but annealing was performed at 68°C.
- Fragment III was purified on an agarose gel and digested with BsrGI and BspEI (Biolabs), purified and subsequently cloned into the corresponding sites of the pEF-DHFR-anti EpCAM (M79) x anti-CD3 cloning vector. The cloned region was verified by restriction digests and by DNA-sequencing.
- CHO-cells lacking DHFR gene were maintained in alpha MEM medium (Life Technologies, cat.no: 32561) supplemented with 10% fetal calf serum (Life Technologies, heat inactivated at 65°C for 30 minutes) and with HT (Hypoxanthin and Thymidine; Life Technologies).
- the cells were transfected with pEF-DHFR-3- 1xanti-CD3 (VH5/VL2) (SEQ ID NO.: 48) and pEF-DHFR-5-10xanti-CD3 (VH5/VL2) (SEQ ID NO.:62), using Lipofectamine 2000 kit® (Invitrogen) according to the instructions provided by the Manufacturer. After 48 hrs.
- selection was performed in selection medium (alpha MEM medium containing heat inactivated 10% dialysed fetal calf serum (Life Technologies). After 3-4 weeks cell culture supernatant was collected and centrifuged at 4°C for 10 minutes at 300g to remove cells and cell debris. The supernatant containing the bispecific antibody was stored at -20°C till further analysis.
- selection medium alpha MEM medium containing heat inactivated 10% dialysed fetal calf serum (Life Technologies). After 3-4 weeks cell culture supernatant was collected and centrifuged at 4°C for 10 minutes at 300g to remove cells and cell debris. The supernatant containing the bispecific antibody was stored at -20°C till further analysis.
- the cells were washed twice in FACS buffer (phosphate-buffered saline containing 1% fetal calf serum (FCS) and 0.05% sodium azide) and incubated with mouse anti-His antibody (Dianova,DIA910) for 60 min. at 4°C. Washing steps were performed as above.
- FACS buffer phosphate-buffered saline containing 1% fetal calf serum (FCS) and 0.05% sodium azide
- the cells were finally incubated either with goat anti-mouse Ig-FITC-conjugated antibody (BD 550003) or with anti-mouse IgG conjugated with PE (Sigma, P8547). After washing steps, 10000 events were analysed using FACS Calibur (B&D). The results of the binding assays are shown in Figure 16.
- the constructs 3-1xanti-CD3 (VH5/VL2) (SEQ ID NO..49) and 5-10xanti-CD3 (SEQ ID NO.:63) showed strong binding to CD3 on Jurkat cells and to CD19 on Kato cells.
- the constructs comprising a deimmunized anti-CD3 region and an EpCAM-specific region were purified with a two-step purification process including immobilized metal affinity chromatography (IMAC) and gel filtration.
- IMAC immobilized metal affinity chromatography
- IMAC Metal affinity chromatography
- gel filtration were carried out as demonstrated in example 3.2.
- a further high-resolution cation exchange chromatography was performed on a MiniS column (Amersham), equilibrated with 20mM MES buffer pH 5.5. The sample was diluted 1:3 with the same buffer before loading to the column.
- Bound protein was eluted with a 0-30% gradient gradient of 1 M NaCI in equilibration buffer. The eluted protein fractions were tested in the bioactivity assay.
- Table 14 shows the yields of the purified deimmunized EpCAM constructs. All the constructs could be efficiently produced. Surprisingly, the construct 5-10xanti-CD3 (VH5/VL2) (SEQ ID NO.:63) had an extremely good yield of 2200 ⁇ g/l.
- CHO cells were transfected with epithelial cell adhesion molecule (EpCAM).
- EpCAM epithelial cell adhesion molecule
- CHO-EpCAM (1.5x10 7 ) cells were washed free of serum two times with PBS and incubated with PKH26 dye (Sigma-Aldrich Co.) according to the manufacturers instructions. After staining, cells were washed two times with RPMI/10% FCS.
- the CD4-positive T cell clone CB15 was kindly provided by Dr. Fickenscher, University of Er Weg/Nuernberg, Germany. Cells were cultured as recommended by the suppliers. The resulting cell suspension contained 400.000 target and 2 x 10 6 effector cells per ml. 50 ⁇ l of the mixture was used per well in a 96 well round bottom plate.
- Antibodies were diluted in RPMI/10% FCS to the required concentration and 50 ⁇ l of this solution was added to the cell suspension. A standard reaction was incubated for 16 h at 37°C / 5% CO 2 . Propidium iodide was added to a final concentration of 1 ⁇ g/ml. After 10 min of incubation at room temperature cells were analysed by FACS. PKH26 fluorescence was used for positive identification of target cells. Cytotoxicity was measured as ratio of PI positive over all target cells. Sigmoidal dose response curves typically had R2 values >0.97 as determined by Prism Software (GraphPad Software Inc., San Diego, USA). The results of the cytotoxic assays are shown in Figures 17 and 18.
- Example 8.5 Comparison of the productivity of bispecific molecules comprising an EpCAM binding part and a deimmunized CD3 binding part in CHO cells
- CHO cell lines producing deimmunized (CHO-DHFR-) and non-deimmunized (CHO- DHFR- or CHO-K1) were cultivated in HyQ PF CHO LS medium + 4 mM L-Glutamine in a CO 2 incubator at 37°C and 5% CO 2 . Cell numbers and viability were determined using Trypan Blue. Cell density was set to 1-2x10 5 cell/ml.
- Cells were transferred to spinner flasks and thus adjusted to conditions of a stirred culture. Operational parameter settings were 80 rpm, 37°C and 5% CO 2 with gassing in a CO 2 incubator. Culture volume was in the 100-500 ml-range and cell density at inoculation in the range of 1-2x10 5 cells/ml. As for the subcultivation in T-flasks, cultures were centrifuged and resuspended in fresh pre-warmed medium at each passage. Cell density was set to 1-2x10 5 cells/ml.
- rProtein L is a recombinant form of the immunoglobulin- binding Protein L produced by Peptostreptococcus magnus. It has four binding domains and binds immunoglobulin through the light chain (K). Bispecific molecules, which contain variable domains from two different light chains respectively parent antibodies, are also bound by rProtein L.
- Microtiter plates were coated with rProtein L in PBS buffer (2 ⁇ g rProtein L/ml PBS buffer) overnight at 2-8°C. Following coating, remaining adsorption sites were blocked with of blocking buffer (2% BSA in PBS buffer). Then, the plates were frozen and stored at ⁇ 18°C. Before use, the plates were thawed and washed with washing buffer (0.05% Tween 20 in PBS buffer) to remove the mixture of coating solution and blocking buffer.
- inventive 5-10xanti-CD3 (VH5/VL2) construct demonstrated much higher specific productivity (at least five times higher) than the prior art bispecific non- deimmunized EpCAM and CD3 binding antibody.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020127021984A KR20120125634A (ko) | 2003-10-16 | 2004-10-15 | 다중특이적 탈면역화된 cd3-바인더 |
JP2006534709A JP4948174B2 (ja) | 2003-10-16 | 2004-10-15 | 多重特異的脱免疫cd3−結合物質 |
BRPI0415457-6A BRPI0415457A (pt) | 2003-10-16 | 2004-10-15 | constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo |
MXPA06004035A MXPA06004035A (es) | 2003-10-16 | 2004-10-15 | Aglutinantes cd3 de-inmunizados multi-especificos. |
SI200431621T SI1673398T1 (sl) | 2003-10-16 | 2004-10-15 | Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule |
EP04790488A EP1673398B1 (en) | 2003-10-16 | 2004-10-15 | Multispecific deimmunized cd3-binders |
KR1020067009529A KR101229731B1 (ko) | 2003-10-16 | 2004-10-15 | 다중특이적 탈면역화된 cd3-바인더 |
AT04790488T ATE493441T1 (de) | 2003-10-16 | 2004-10-15 | Multispezifische deimmunisierte cd3-bindende moleküle |
DK04790488.3T DK1673398T3 (da) | 2003-10-16 | 2004-10-15 | Multispecifikke, deimmuniserede CD3-bindere |
PL04790488T PL1673398T3 (pl) | 2003-10-16 | 2004-10-15 | Multispecyficzne deimmunizowane cząsteczki wiążące CD3 |
AU2004283850A AU2004283850C1 (en) | 2003-10-16 | 2004-10-15 | Multispecific deimmunized CD3-binders |
NZ546173A NZ546173A (en) | 2003-10-16 | 2004-10-15 | Multispecific deimmunized CD3-binders |
DE602004030811T DE602004030811D1 (de) | 2003-10-16 | 2004-10-15 | Multispezifische deimmunisierte cd3-bindende moleküle |
CA2542239A CA2542239C (en) | 2003-10-16 | 2004-10-15 | Multispecific deimmunized cd3-binders |
US10/572,740 US8076459B2 (en) | 2003-10-16 | 2004-10-15 | Multispecfic deimmunized CD3-binders |
IL174902A IL174902A (en) | 2003-10-16 | 2006-04-10 | Non-neutralized and multi-specific 3cd binders, nucleic acid sequence encoding them, process for their preparation, preparation, kit, vector, surrogate cell and their use |
NO20062117A NO340900B1 (no) | 2003-10-16 | 2006-05-11 | Cytotoksiske aktive CD3 spesifikke bindingskonstrukt, fremgangsmåte for fremstilling,nukleinsyresekvens, vektor, vert, sammensetning, farmasøytisk sammensetning og et kit |
HK06108878.4A HK1086846A1 (en) | 2003-10-16 | 2006-08-10 | Multispecific deimmunized cd3-binders |
IL208795A IL208795A0 (en) | 2003-10-16 | 2010-10-18 | Multispecific deimmunized cd3-binders |
HR20110187T HRP20110187T1 (hr) | 2003-10-16 | 2011-03-14 | Multispecifične deimunizirane tvari koje vežu cd3 |
US13/323,206 US9102736B2 (en) | 2003-10-16 | 2011-12-12 | Multispecific deimmunized CD3-binders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03023581 | 2003-10-16 | ||
EP03023581.6 | 2003-10-16 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/572,740 A-371-Of-International US8076459B2 (en) | 2003-10-16 | 2004-10-15 | Multispecfic deimmunized CD3-binders |
US13/323,206 Continuation US9102736B2 (en) | 2003-10-16 | 2011-12-12 | Multispecific deimmunized CD3-binders |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005040220A1 true WO2005040220A1 (en) | 2005-05-06 |
Family
ID=34486072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/011646 WO2005040220A1 (en) | 2003-10-16 | 2004-10-15 | Multispecific deimmunized cd3-binders |
Country Status (24)
Country | Link |
---|---|
US (2) | US8076459B2 (hr) |
EP (2) | EP1673398B1 (hr) |
JP (2) | JP4948174B2 (hr) |
KR (2) | KR101229731B1 (hr) |
CN (1) | CN100453556C (hr) |
AT (1) | ATE493441T1 (hr) |
AU (1) | AU2004283850C1 (hr) |
BR (1) | BRPI0415457A (hr) |
CA (1) | CA2542239C (hr) |
CY (1) | CY1112891T1 (hr) |
DE (1) | DE602004030811D1 (hr) |
DK (1) | DK1673398T3 (hr) |
ES (1) | ES2358427T3 (hr) |
HK (1) | HK1086846A1 (hr) |
HR (1) | HRP20110187T1 (hr) |
IL (2) | IL174902A (hr) |
MX (1) | MXPA06004035A (hr) |
NO (1) | NO340900B1 (hr) |
NZ (1) | NZ546173A (hr) |
PL (1) | PL1673398T3 (hr) |
RU (1) | RU2401843C2 (hr) |
SI (1) | SI1673398T1 (hr) |
WO (1) | WO2005040220A1 (hr) |
ZA (1) | ZA200601699B (hr) |
Cited By (155)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007068354A1 (en) | 2005-12-16 | 2007-06-21 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
WO2007071426A1 (en) | 2005-12-21 | 2007-06-28 | Micromet Ag | Pharmaceutical compositions with resistance to soluble cea |
EP1981532A2 (en) * | 2005-12-21 | 2008-10-22 | Medimmune, Inc. | Epha2 bite molecules and uses thereof |
EP2121756A1 (en) * | 2006-12-20 | 2009-11-25 | MMR Information Systems, Inc. | Antibodies and methods for making and using them |
US20100150918A1 (en) * | 2007-04-03 | 2010-06-17 | Micromet Ag | Cross-species-specific binding domain |
WO2011033105A1 (en) | 2009-09-18 | 2011-03-24 | Micromet Ag | Dosage regimen for administering an epcamxcd3 bispecific antibody |
US20110262440A1 (en) * | 2008-11-07 | 2011-10-27 | Micromet Ag | Treatment of pediatric acute lymphoblastic leukemia |
JP2012504402A (ja) * | 2008-10-01 | 2012-02-23 | マイクロメット アーゲー | PSCA×CD3、CD19×CD3、C−MET×CD3、エンドシアリン×CD3、EpCAM×CD3、IGF−1R×CD3、またはFAPアルファ×CD3の異種間特異的二重特異性単鎖抗体 |
US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
WO2013083809A1 (en) | 2011-12-09 | 2013-06-13 | Amgen Research (Munich) Gmbh | Prevention of adverse effects caused by epcamxcd3 bispecific antibodies |
WO2013128027A1 (en) | 2012-03-01 | 2013-09-06 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
US20130323247A1 (en) * | 2008-11-07 | 2013-12-05 | Micromet Ag | Treatment of acute lymphoblastic leukemia |
WO2014047231A1 (en) * | 2012-09-21 | 2014-03-27 | Regeneron Pharmaceuticals, Inc. | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
US20140099254A1 (en) * | 2012-08-14 | 2014-04-10 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US8853366B2 (en) | 2001-01-17 | 2014-10-07 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
WO2015070061A1 (en) * | 2013-11-07 | 2015-05-14 | Memorial Sloan-Kettering Cancer Center | Anti-wt1/hla bi-specific antibody |
AU2011320314B2 (en) * | 2010-10-29 | 2015-08-06 | Immunogen, Inc. | Novel EGFR-binding molecules and immunoconjugates thereof |
US9101609B2 (en) | 2008-04-11 | 2015-08-11 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
US20150231241A1 (en) * | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
WO2016016859A1 (en) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs |
AU2013202392B2 (en) * | 2006-12-20 | 2016-02-25 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
EP2352763B1 (en) | 2008-10-01 | 2016-04-13 | Amgen Research (Munich) GmbH | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
EP2356153B1 (en) | 2008-10-01 | 2016-05-04 | Amgen Research (Munich) GmbH | Cross-species-specific psmaxcd3 bispecific single chain antibody |
US20160176980A1 (en) * | 2012-08-14 | 2016-06-23 | Ibc Pharmaceuticals, Inc. | T-Cell Redirecting Bispecific Antibodies for Treatment of Disease |
WO2016166360A1 (en) | 2015-04-17 | 2016-10-20 | Bayer Pharma Aktiengesellschaft | Bispecific antibody constructs for cdh3 and cd3 |
AU2013202375B2 (en) * | 2005-12-16 | 2016-10-27 | Amgen Research (Munich) Gmbh | Means and Methods for the Treatment of Tumorous Diseases |
WO2017021370A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs binding egfrviii and cd3 |
WO2017021526A1 (en) | 2015-08-05 | 2017-02-09 | Amgen Research (Munich) Gmbh | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers |
WO2017021349A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs binding dll3 and cd3 |
WO2017021354A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Antibody constructs for cd70 and cd3 |
WO2017021362A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Antibody constructs for flt3 and cd3 |
WO2017021356A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs binding mesothelin and cd3 |
US9782478B1 (en) | 2011-04-22 | 2017-10-10 | Aptevo Research And Development Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
WO2017182427A1 (en) | 2016-04-19 | 2017-10-26 | Amgen Research (Munich) Gmbh | Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
US20170362299A1 (en) * | 2014-12-08 | 2017-12-21 | 1Globe Biomedical Co., Ltd. | Soluble Universal ADCC-Enhancing Synthetic Fusion Gene and Peptide Technology and Its Use Thereof |
WO2018141910A1 (en) | 2017-02-02 | 2018-08-09 | Amgen Research (Munich) Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
US10093736B2 (en) | 2012-11-13 | 2018-10-09 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
WO2018204907A1 (en) | 2017-05-05 | 2018-11-08 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
US10143748B2 (en) | 2005-07-25 | 2018-12-04 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
WO2018220099A1 (en) | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
WO2019043020A1 (en) | 2017-08-28 | 2019-03-07 | Psioxus Therapeutics Limited | ADENOVIRUS EQUIPPED WITH A BISPECIFIC T CELL ACTIVATOR (BITE) |
US10239952B2 (en) | 2011-04-01 | 2019-03-26 | Memorial Sloan Kettering Cancer Center | Anti-WT1/HLA bi-specific antibody |
EP3447072A3 (en) * | 2013-03-05 | 2019-05-22 | Baylor College of Medicine | Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy |
US10301391B2 (en) | 2016-02-03 | 2019-05-28 | Amgen Research (Munich) Gmbh | BCMA and CD3 bispecific T cell engaging antibody constructs |
WO2019118426A1 (en) | 2017-12-11 | 2019-06-20 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
WO2019133961A1 (en) | 2017-12-29 | 2019-07-04 | Amgen Inc. | Bispecific antibody construct directed to muc17 and cd3 |
WO2019140196A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Anti-pd-1 antibodies and methods of treatment |
EP2780374B1 (en) | 2011-11-15 | 2019-08-21 | Amgen Research (Munich) GmbH | Binding molecules for bcma and cd3 |
US10414824B2 (en) | 2002-11-22 | 2019-09-17 | Ganymed Pharmaceuticals Ag | Genetic products differentially expressed in tumors and the use thereof |
US10435453B2 (en) | 2014-02-07 | 2019-10-08 | Mcmaster University | Trifunctional T cell-antigen coupler and methods and uses thereof |
US10550193B2 (en) | 2014-03-19 | 2020-02-04 | Regeneron Pharmaceuticals, Inc. | Methods and antibody compositions for tumor treatment |
WO2020025792A1 (en) | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
WO2020025532A1 (en) | 2018-07-30 | 2020-02-06 | Amgen Research (Munich) Gmbh | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3 |
WO2020025596A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Research (Munich) Gmbh | Dosing regimen for bcma-cd3 bispecific antibodies |
CN110872356A (zh) * | 2018-09-03 | 2020-03-10 | 广西慧宝源健康产业有限公司 | 双特异性抗体及其使用方法 |
WO2020069303A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Antibodies against soluble bcma |
WO2020076970A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
WO2020077212A1 (en) | 2018-10-11 | 2020-04-16 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
WO2020076992A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
WO2020076977A2 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
WO2020086635A1 (en) | 2018-10-23 | 2020-04-30 | Amgen Inc. | Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions |
US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
US10662244B2 (en) | 2014-11-17 | 2020-05-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3XCD20 bispecific antibody |
US10669337B2 (en) | 2014-07-25 | 2020-06-02 | Cytomx Therapeutics, Inc. | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same |
WO2020159838A1 (en) | 2019-01-28 | 2020-08-06 | Amgen Inc. | A continuous manufacturing process for biologics manufacturing by integration of drug substance and drug product processes |
US10781264B2 (en) | 2016-02-03 | 2020-09-22 | Amgen Research (Munich) Gmbh | PSMA and CD3 bispecific T cell engaging antibody constructs |
WO2020247854A1 (en) | 2019-06-07 | 2020-12-10 | Amgen Inc. | Bispecific binding constructs with selectively cleavable linkers |
WO2020252442A1 (en) | 2019-06-13 | 2020-12-17 | Amgen Inc. | Automated biomass-based perfusion control in the manufacturing of biologics |
WO2021050640A1 (en) | 2019-09-10 | 2021-03-18 | Amgen Inc. | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity |
WO2021041300A3 (en) * | 2019-08-23 | 2021-04-01 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
EP3819007A1 (en) | 2019-11-11 | 2021-05-12 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
EP3819312A1 (en) | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
WO2021091906A1 (en) | 2019-11-04 | 2021-05-14 | Amgen Inc. | Methods for treating leukemia |
WO2021097344A1 (en) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
WO2021127528A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
WO2021146336A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
WO2021146328A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Formulations for protein therapeutics |
WO2021150824A1 (en) | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
WO2021158469A1 (en) | 2020-02-03 | 2021-08-12 | Amgen Inc. | Multivariate bracketing approach for sterile filter validation |
US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
WO2021183861A1 (en) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
WO2021188851A1 (en) | 2020-03-19 | 2021-09-23 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
US11155622B2 (en) | 2015-12-17 | 2021-10-26 | Psioxus Therapeutics Limited | Virus encoding an anti-TCR-complex antibody or fragment |
US11161906B2 (en) | 2013-07-25 | 2021-11-02 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
US11173186B2 (en) | 2013-06-14 | 2021-11-16 | Psioxus Therapeutics Limited | Dosing regime and formulations for type B adenovirus |
WO2021236638A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
WO2021243320A2 (en) | 2020-05-29 | 2021-12-02 | Amgen Inc. | Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3 |
WO2021247812A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Bispecific binding constructs |
US11198737B2 (en) | 2017-10-12 | 2021-12-14 | Mcmaster University | T cell-antigen coupler with Y177 mutation and methods of uses thereof |
US20220002398A1 (en) * | 2018-06-07 | 2022-01-06 | Oncoone Research & Development Gmbh | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT |
WO2022056267A1 (en) | 2020-09-11 | 2022-03-17 | Amgen Inc. | Materials and methods to reduce protein aggregation |
WO2022060901A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
WO2022060878A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for treating prostate cancer |
US11306142B2 (en) | 2017-07-05 | 2022-04-19 | Ucl Business Ltd | Bispecific antibodies to ROR1 and CD3 |
WO2022096704A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
WO2022096716A2 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Multitargeting bispecific antigen-binding molecules of increased selectivity |
WO2022096698A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Polypeptide constructs binding to cd3 |
WO2022097068A1 (en) | 2020-11-05 | 2022-05-12 | Dcprime B.V. | Use of tumor-independent antigens in immunotherapies |
WO2022096700A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Research (Munich) Gmbh | Polypeptide constructs selectively binding to cldn6 and cd3 |
WO2022103781A1 (en) | 2020-11-10 | 2022-05-19 | Amgen Inc. | Methods for administering a bcma x cd3 binding molecule |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
WO2022120033A1 (en) | 2020-12-03 | 2022-06-09 | Amgen Inc. | Immunoglobuline constructs with multiple binding domains |
EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
US11390681B2 (en) | 2020-04-29 | 2022-07-19 | TeneoTwo, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
EP3891181A4 (en) * | 2018-12-04 | 2022-08-17 | Novartis AG | BINDING MOLECULES AGAINST CD3 AND USES THEREOF |
US11419933B2 (en) | 2016-01-25 | 2022-08-23 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs |
US11434299B2 (en) | 2016-12-21 | 2022-09-06 | Teneobio, Inc. | Anti-BCMA heavy chain-only antibodies |
US11434302B2 (en) | 2016-02-03 | 2022-09-06 | Amgen Research (Munich) Gmbh | Bispecific T cell engaging antibody constructs |
US11439678B2 (en) | 2013-10-25 | 2022-09-13 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
WO2022192504A1 (en) | 2021-03-10 | 2022-09-15 | Amgen Inc. | Methods for purification of recombinant proteins |
WO2022191971A1 (en) | 2021-03-10 | 2022-09-15 | Amgen Inc. | Parallel chromatography systems and methods |
US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
WO2022212831A1 (en) | 2021-04-02 | 2022-10-06 | Amgen Inc. | Mageb2 binding constructs |
US11466083B2 (en) | 2017-07-05 | 2022-10-11 | Ucl Business Ltd | ROR1 antibodies |
WO2022228706A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
US11492409B2 (en) | 2018-06-01 | 2022-11-08 | Novartis Ag | Binding molecules against BCMA and uses thereof |
WO2022234102A1 (en) | 2021-05-06 | 2022-11-10 | Amgen Research (Munich) Gmbh | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
US11505606B2 (en) | 2016-09-14 | 2022-11-22 | Teneobio, Inc. | CD3 binding antibodies |
WO2022243347A1 (en) | 2021-05-18 | 2022-11-24 | Christian-Albrechts-Universität Zu Kiel | Co-stimulatory multispecific antibodies |
WO2022246244A1 (en) | 2021-05-21 | 2022-11-24 | Aptevo Research And Development Llc | Dosing regimens for protein therapeutics |
US11530274B2 (en) | 2018-07-02 | 2022-12-20 | Amgen Inc. | Anti-STEAP1 antigen-binding protein |
US11541103B2 (en) | 2017-08-03 | 2023-01-03 | Amgen Inc. | Interleukin-21 mutein/ anti-PD-1 antibody conjugates |
EP3969479A4 (en) * | 2019-05-14 | 2023-02-08 | Harpoon Therapeutics, Inc. | EPCAM-BINDING PROTEINS AND METHODS OF USE |
US11590223B2 (en) | 2018-08-31 | 2023-02-28 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies |
US11613572B2 (en) | 2016-06-21 | 2023-03-28 | Teneobio, Inc. | CD3 binding antibodies |
US11617767B2 (en) | 2020-11-20 | 2023-04-04 | Simcere Innovation, Inc. | Armed dual CAR-T compositions and methods for cancer immunotherapy |
WO2023076318A1 (en) | 2021-10-27 | 2023-05-04 | Amgen Inc. | Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy |
WO2023078968A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
WO2023079493A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
WO2023110918A1 (en) | 2021-12-14 | 2023-06-22 | Cdr-Life Ag | Dual mhc-targeting t cell engager |
US11723925B2 (en) | 2017-07-05 | 2023-08-15 | Ucl Business Ltd | ROR1 CAR T-cells |
WO2023164474A1 (en) | 2022-02-23 | 2023-08-31 | Amgen Inc. | Cancer treatment targeting dll3 |
US11744892B2 (en) | 2017-09-08 | 2023-09-05 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
US11807692B2 (en) | 2018-09-25 | 2023-11-07 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
EP4273252A2 (en) | 2016-08-29 | 2023-11-08 | Akamis Bio Limited | Adenovirus armed with bispecific t cell engager (bite) |
WO2023218027A1 (en) | 2022-05-12 | 2023-11-16 | Amgen Research (Munich) Gmbh | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
US11905326B2 (en) | 2019-06-14 | 2024-02-20 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to CD22 and CD3 |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
WO2024056758A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
US11970540B2 (en) | 2017-06-20 | 2024-04-30 | Teneobio, Inc. | Anti-BCMA heavy chain-only antibodies |
WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
US11976125B2 (en) | 2017-10-13 | 2024-05-07 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
US11998580B2 (en) | 2018-01-31 | 2024-06-04 | Akamis Bio Limited | Group B adenovirus-containing formulation |
US12016923B2 (en) | 2021-06-01 | 2024-06-25 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 T cell-antigen couplers and uses thereof |
US12084518B2 (en) | 2015-05-21 | 2024-09-10 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
WO2024187062A1 (en) | 2023-03-08 | 2024-09-12 | Amgen Inc. | Controlled-ice nucleation lyophilization process for bispecific molecules |
US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
CA2646329C (en) | 2006-03-20 | 2018-07-03 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
DE202007016718U1 (de) * | 2007-02-21 | 2008-04-03 | K.L. Kaschier- Und Laminier Gmbh | Airbagdeckelscharnier mit kraftaufnehmendem System |
WO2008119566A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
EP2197491A4 (en) * | 2007-09-04 | 2011-01-12 | Univ California | HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER |
WO2009046294A2 (en) * | 2007-10-03 | 2009-04-09 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
JP5906090B2 (ja) * | 2009-02-17 | 2016-04-20 | コーネル・リサーチ・ファンデーション・インコーポレイテッドCornell Research Foundation, Incorporated | 癌の診断のための方法およびキットならびに治療価の推定 |
CA2782333C (en) | 2009-12-02 | 2019-06-04 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
WO2012066058A1 (en) | 2010-11-16 | 2012-05-24 | Boehringer Ingelheim International Gmbh | Agents and methods for treating diseases that correlate with bcma expression |
US9249217B2 (en) | 2010-12-03 | 2016-02-02 | Secretary, DHHS | Bispecific EGFRvIII x CD3 antibody engaging molecules |
DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
RU2605390C2 (ru) * | 2011-08-23 | 2016-12-20 | Рош Гликарт Аг | Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения |
PT2802607T (pt) * | 2012-01-13 | 2018-01-03 | Univ Wuerzburg J Maximilians | Complementação funcional bipartida induzida por duplo antigénio |
GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
CA2876133C (en) | 2012-06-07 | 2017-06-06 | Duke University | Human bispecific egfrviii antibody engaging molecules |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
US9758591B2 (en) | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
CN104342453A (zh) * | 2013-08-06 | 2015-02-11 | 深圳先进技术研究院 | 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用 |
EP3620470B1 (en) | 2013-10-11 | 2023-07-26 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Tem8 antibodies and their use |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
BR112016022055A2 (pt) * | 2014-03-26 | 2017-10-24 | Cell Medica Switzerland Ag | elementos de ligação ao tnf alfa |
KR102380402B1 (ko) | 2014-04-03 | 2022-03-31 | 아이쥐엠 바이오사이언스 인코포레이티드 | 변형된 j-사슬 |
EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
US10160795B2 (en) | 2014-11-14 | 2018-12-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to Ebola virus glycoprotein and their use |
WO2016138160A1 (en) | 2015-02-24 | 2016-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
IL297997A (en) | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | CD20 binding compounds and their uses |
EP3683233A1 (en) | 2015-03-20 | 2020-07-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to gp120 and their use |
CN114634943A (zh) | 2015-05-18 | 2022-06-17 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
BR112017025479A2 (pt) | 2015-05-29 | 2018-08-07 | Amphivena Therapeutics Inc | métodos para utilizar proteínas de ligação cd33 e cd3 biespecíficas |
EP4137158A1 (en) | 2015-08-07 | 2023-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
CN108135968A (zh) | 2015-08-28 | 2018-06-08 | 阿穆尼克斯运营公司 | 嵌合多肽组装体及其制备和使用方法 |
EP3355913A1 (en) | 2015-09-30 | 2018-08-08 | IGM Biosciences A/S | Binding molecules with modified j-chain |
DK3356401T3 (da) * | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
WO2017062748A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
US10752686B2 (en) | 2015-10-30 | 2020-08-25 | Zonhon Biopharma Institute Inc. | Bispecific antibody binding to human CD26 and human CD3, production method therefor and use thereof |
WO2017079479A1 (en) | 2015-11-03 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Neutralizing antibodies to hiv-1 gp41 and their use |
PT3377103T (pt) | 2015-11-19 | 2021-05-26 | Revitope Ltd | Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas |
TW202302631A (zh) * | 2016-03-08 | 2023-01-16 | 日商武田藥品工業股份有限公司 | 可誘導性結合蛋白和使用方法 |
WO2017167350A1 (en) * | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
MY196869A (en) | 2016-06-27 | 2023-05-05 | Univ California | Cancer treatment combinations |
EA201990218A1 (ru) | 2016-07-06 | 2019-07-31 | Селджин Корпорейшн | Антитела с низкой иммуногенностью и их применения |
EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法 |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
WO2018148660A1 (en) | 2017-02-10 | 2018-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
CA3235295A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
CN108690138A (zh) * | 2017-04-12 | 2018-10-23 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用 |
CN107501412A (zh) * | 2017-10-11 | 2017-12-22 | 深圳精准医疗科技有限公司 | 突变型双特异性抗体及其应用 |
GB201717966D0 (en) * | 2017-10-31 | 2017-12-13 | Xenikos Bv | Immunotoxins, formulations thereof and their use in medicine |
EP3724223A1 (en) | 2018-01-02 | 2020-10-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
WO2019165122A1 (en) | 2018-02-21 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
KR20210087472A (ko) | 2018-11-01 | 2021-07-12 | 산동 뉴 타임 파마슈티칼 코., 리미티드. | 이중 특이성 항체 및 그 용도 |
US20220089694A1 (en) | 2018-12-20 | 2022-03-24 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
WO2020181140A1 (en) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
US20220227853A1 (en) | 2019-05-03 | 2022-07-21 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
AU2020299382A1 (en) | 2019-07-02 | 2022-01-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind EGFRvIII and their use |
WO2021146272A1 (en) * | 2020-01-13 | 2021-07-22 | The Regents Of The University Of California | Methods for treating viral infections |
BR112022025381A2 (pt) | 2020-06-11 | 2023-01-24 | Provention Bio Inc | Métodos e composições para prevenir diabetes tipo 1 |
WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
WO2022173670A1 (en) | 2021-02-09 | 2022-08-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies targeting the spike protein of coronaviruses |
CN117396502A (zh) | 2021-02-09 | 2024-01-12 | 佐治亚大学研究基金会有限公司 | 针对肺炎球菌抗原的人类单克隆抗体 |
CA3232223A1 (en) | 2021-09-17 | 2023-03-23 | Ying Fu | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
WO2023087255A1 (zh) * | 2021-11-19 | 2023-05-25 | 武汉友芝友生物制药股份有限公司 | 双特异性抗体及其应用 |
WO2023154824A1 (en) | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that broadly target coronaviruses |
WO2023192881A1 (en) | 2022-03-28 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2023230626A2 (en) * | 2022-05-27 | 2023-11-30 | Bighat Biosciences, Inc. | Ph-selective anti-cd3 antibodies and use of the same |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
WO2024082269A1 (zh) * | 2022-10-21 | 2024-04-25 | 武汉友芝友生物制药股份有限公司 | 双特异性抗体在免疫细胞治疗方面的应用 |
WO2024137381A1 (en) | 2022-12-19 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies for treating sars-cov-2 infection |
WO2024138155A1 (en) | 2022-12-22 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992010755A1 (en) | 1990-12-05 | 1992-06-25 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
EP0620276A1 (en) * | 1989-12-21 | 1994-10-19 | Celltech Therapeutics Limited | Humanised antibodies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
WO2000005268A1 (en) | 1998-07-21 | 2000-02-03 | Btg International Ltd. | Hybrid human/rodent igg antibody to cd3, and methods of its construction |
WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
EP1025854A1 (de) | 1999-02-08 | 2000-08-09 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung depletorisch oder mitogen wirkender Antikörper gegen CD3/TCR in der Immuntherapie |
WO2000067795A1 (en) | 1999-05-10 | 2000-11-16 | Immunomedics, Inc. | Immunotherapy of b-cell malignancies using anti-cd22 antibodies |
WO2001047953A2 (en) | 1999-12-23 | 2001-07-05 | Mueller Hermelink Hans Konrad | Antibodies against plasma cells |
WO2002004021A1 (en) | 2000-07-12 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
WO2002012899A2 (en) | 2000-08-03 | 2002-02-14 | Merck Patent Gmbh | Peptides presented by cells |
US20020028178A1 (en) | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
WO2002022212A2 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
WO2002066514A2 (en) * | 2001-02-19 | 2002-08-29 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
WO2002080987A1 (en) | 2001-04-09 | 2002-10-17 | Progenics Pharmaceuticals, Inc. | Anti-cd19 immunotoxins |
US6491916B1 (en) * | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
WO2003004648A1 (fr) | 2001-05-24 | 2003-01-16 | Institute Of Genetics And Devel. Biol., Cas | Anticorps bispecifique anticancer de l'ovaire humain-anti cd3 |
US20040162411A1 (en) * | 2002-10-11 | 2004-08-19 | Micromet Ag | Potent T cell modulating molecules |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361549A (en) * | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
JP3854306B2 (ja) * | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ヒト化及びキメラモノクローナル抗体 |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
WO1994029469A2 (en) | 1993-06-07 | 1994-12-22 | Vical Incorporated | Plasmids suitable for gene therapy |
CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
DE19725586C2 (de) * | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
EP1032660B1 (en) | 1997-11-17 | 2009-11-04 | Micromet AG | Method of identifying binding site domains that retain the capacity of binding to an epitop |
WO2002069232A2 (en) | 2001-02-19 | 2002-09-06 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
AU2004242846A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
-
2004
- 2004-10-15 KR KR1020067009529A patent/KR101229731B1/ko active IP Right Grant
- 2004-10-15 NZ NZ546173A patent/NZ546173A/en unknown
- 2004-10-15 EP EP04790488A patent/EP1673398B1/en active Active
- 2004-10-15 SI SI200431621T patent/SI1673398T1/sl unknown
- 2004-10-15 KR KR1020127021984A patent/KR20120125634A/ko not_active Application Discontinuation
- 2004-10-15 MX MXPA06004035A patent/MXPA06004035A/es active IP Right Grant
- 2004-10-15 RU RU2006116459/10A patent/RU2401843C2/ru active
- 2004-10-15 DK DK04790488.3T patent/DK1673398T3/da active
- 2004-10-15 AU AU2004283850A patent/AU2004283850C1/en active Active
- 2004-10-15 AT AT04790488T patent/ATE493441T1/de active
- 2004-10-15 JP JP2006534709A patent/JP4948174B2/ja active Active
- 2004-10-15 BR BRPI0415457-6A patent/BRPI0415457A/pt not_active Application Discontinuation
- 2004-10-15 ES ES04790488T patent/ES2358427T3/es active Active
- 2004-10-15 CA CA2542239A patent/CA2542239C/en active Active
- 2004-10-15 PL PL04790488T patent/PL1673398T3/pl unknown
- 2004-10-15 DE DE602004030811T patent/DE602004030811D1/de active Active
- 2004-10-15 ZA ZA200601699A patent/ZA200601699B/en unknown
- 2004-10-15 US US10/572,740 patent/US8076459B2/en active Active
- 2004-10-15 EP EP10177720.9A patent/EP2292664B1/en not_active Revoked
- 2004-10-15 CN CNB2004800301501A patent/CN100453556C/zh active Active
- 2004-10-15 WO PCT/EP2004/011646 patent/WO2005040220A1/en active Application Filing
-
2006
- 2006-04-10 IL IL174902A patent/IL174902A/en active IP Right Grant
- 2006-05-11 NO NO20062117A patent/NO340900B1/no unknown
- 2006-08-10 HK HK06108878.4A patent/HK1086846A1/xx unknown
-
2010
- 2010-10-18 IL IL208795A patent/IL208795A0/en unknown
-
2011
- 2011-03-14 HR HR20110187T patent/HRP20110187T1/hr unknown
- 2011-03-28 CY CY20111100326T patent/CY1112891T1/el unknown
- 2011-12-12 US US13/323,206 patent/US9102736B2/en active Active
-
2012
- 2012-01-27 JP JP2012015443A patent/JP5599079B2/ja active Active
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0620276A1 (en) * | 1989-12-21 | 1994-10-19 | Celltech Therapeutics Limited | Humanised antibodies |
WO1992010755A1 (en) | 1990-12-05 | 1992-06-25 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6491916B1 (en) * | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
WO2000005268A1 (en) | 1998-07-21 | 2000-02-03 | Btg International Ltd. | Hybrid human/rodent igg antibody to cd3, and methods of its construction |
WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
EP1025854A1 (de) | 1999-02-08 | 2000-08-09 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung depletorisch oder mitogen wirkender Antikörper gegen CD3/TCR in der Immuntherapie |
WO2000067795A1 (en) | 1999-05-10 | 2000-11-16 | Immunomedics, Inc. | Immunotherapy of b-cell malignancies using anti-cd22 antibodies |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
WO2001047953A2 (en) | 1999-12-23 | 2001-07-05 | Mueller Hermelink Hans Konrad | Antibodies against plasma cells |
WO2002004021A1 (en) | 2000-07-12 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
US20020028178A1 (en) | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
WO2002012899A2 (en) | 2000-08-03 | 2002-02-14 | Merck Patent Gmbh | Peptides presented by cells |
WO2002022212A2 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
US20020058029A1 (en) | 2000-09-18 | 2002-05-16 | Nabil Hanna | Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination |
WO2002066514A2 (en) * | 2001-02-19 | 2002-08-29 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
WO2002080987A1 (en) | 2001-04-09 | 2002-10-17 | Progenics Pharmaceuticals, Inc. | Anti-cd19 immunotoxins |
WO2003004648A1 (fr) | 2001-05-24 | 2003-01-16 | Institute Of Genetics And Devel. Biol., Cas | Anticorps bispecifique anticancer de l'ovaire humain-anti cd3 |
US20040162411A1 (en) * | 2002-10-11 | 2004-08-19 | Micromet Ag | Potent T cell modulating molecules |
Non-Patent Citations (23)
Title |
---|
BLANPAIN, MOL BIOL CELL, vol. 13, 2002, pages 723 - 37 |
CAMERON, J. 'LMMUNOL., vol. 165, 2000, pages 1102 - 1110 |
CHOTHIA, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
CHOTHIA, NATURE, vol. 342, 1989, pages 877 - 883 |
D'SOUZA, NATURE MED., vol. 2, 1996, pages 1293 |
FAUCI, NATURE, vol. 384, 1996, pages 529 |
HAAGEN, CLIN EXP IMMUNOL, vol. 90, 1992, pages 368 - 75 |
HAISMA ET AL., BLOOD, vol. 92, 1998, pages 184 - 190 |
HOFFMAN, J. LMMUNOL., vol. 135, 1985, pages 5 - 8 |
KIPRIYANOV, INT. J. CANCER, vol. 77, 1998, pages 763 - 772 |
KRAFT, J BIO) CHEM., vol. 14, no. 276, 2001, pages 34408 - 18 |
KRAFT, J BIOL CHEM., vol. 14, no. 276, 2001, pages 34408 - 18 |
LIU ET AL., J IMMUNOL, vol. 139, 1987, pages 3521 - 3526 |
MACK, J. EXP. MED., vol. 187, 1998, pages 1215 - 1224 |
MALETZ K ET AL: "Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity", INTERNATIONAL JOURNAL OF CANCER, vol. 93, no. 3, 1 August 2001 (2001-08-01), pages 409 - 416, XP002301955, ISSN: 0020-7136 * |
MONTSERRAT, SEMIN ONCOL, vol. 30, 2003, pages 34 - 39 |
PREMACK, NATURE MED., vol. 2, pages 1174 |
PRESS ET AL., BLOOD, vol. 69/2, 1987, pages 584 - 591 |
SEGERER, KIDNEY INT., vol. 56, 1999, pages 52 - 64 |
SHAN ET AL., J. IMMUNOL, vol. 162, 1999, pages 6589 - 6595 |
TRAUNECKER, EMBO J, vol. 10, 1991, pages 3655 - 9 |
TREON ET AL., SEMIN ONCOL, vol. 27, no. 5, 2000, pages 598 |
UCKUN, PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 8603 - 7 |
Cited By (250)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853366B2 (en) | 2001-01-17 | 2014-10-07 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
US10414824B2 (en) | 2002-11-22 | 2019-09-17 | Ganymed Pharmaceuticals Ag | Genetic products differentially expressed in tumors and the use thereof |
US10307481B2 (en) | 2005-07-25 | 2019-06-04 | Aptevo Research And Development Llc | CD37 immunotherapeutics and uses thereof |
US10143748B2 (en) | 2005-07-25 | 2018-12-04 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
WO2007068354A1 (en) | 2005-12-16 | 2007-06-21 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
JP2009519257A (ja) * | 2005-12-16 | 2009-05-14 | ミクロメット・アクチェンゲゼルシャフト | 腫瘍性疾患を処置するための手段および方法 |
JP2014028840A (ja) * | 2005-12-16 | 2014-02-13 | Amgen Research (Munich) Gmbh | 腫瘍性疾患を処置するための手段および方法 |
AU2013202375B2 (en) * | 2005-12-16 | 2016-10-27 | Amgen Research (Munich) Gmbh | Means and Methods for the Treatment of Tumorous Diseases |
US11154617B2 (en) | 2005-12-16 | 2021-10-26 | Amgen Research (Munich) Gmbh | Means and methods for the treament of B cell non-hodgkin lymphoma and B cell leukemia |
US8007796B2 (en) | 2005-12-16 | 2011-08-30 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
EP1981532A4 (en) * | 2005-12-21 | 2010-06-30 | Medimmune Llc | EPHA2 MOLECULES AND USES THEREOF |
US9695250B2 (en) | 2005-12-21 | 2017-07-04 | Amgen Research (Munich) Gmbh | Pharmaceutical compositions with resistance to soluble CEA |
US9982063B2 (en) | 2005-12-21 | 2018-05-29 | Amgen Research (Munich) Gmbh | Pharmaceutical compositions with resistance to soluble CEA |
EP2527370A1 (en) | 2005-12-21 | 2012-11-28 | Amgen Research (Munich) GmbH | Compounds having resistance to soluble CEA |
EP1981532A2 (en) * | 2005-12-21 | 2008-10-22 | Medimmune, Inc. | Epha2 bite molecules and uses thereof |
WO2007071426A1 (en) | 2005-12-21 | 2007-06-28 | Micromet Ag | Pharmaceutical compositions with resistance to soluble cea |
RU2573893C2 (ru) * | 2005-12-21 | 2016-01-27 | Эмджен Рисерч (Мьюник) Гмбх | Фармацевтические композиции с устойчивостью к растворимому сеа |
US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
EP2121756A4 (en) * | 2006-12-20 | 2011-08-31 | Mmrglobal Inc | ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE |
AU2013202392B2 (en) * | 2006-12-20 | 2016-02-25 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
US8465741B2 (en) | 2006-12-20 | 2013-06-18 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
JP2014028812A (ja) * | 2006-12-20 | 2014-02-13 | Mmr Global Inc | 抗体とその製造法および使用法 |
AU2007338607B2 (en) * | 2006-12-20 | 2013-03-14 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
KR101378302B1 (ko) | 2006-12-20 | 2014-03-28 | 엠엠알글로벌, 인코포레이티드 | 항체 및 이들의 제조 및 사용 방법 |
EP2121756A1 (en) * | 2006-12-20 | 2009-11-25 | MMR Information Systems, Inc. | Antibodies and methods for making and using them |
JP2015145394A (ja) * | 2006-12-20 | 2015-08-13 | エムエムアールグローバル,インコーポレーテッド | 抗体とその製造法および使用法 |
EP2716658A3 (en) * | 2006-12-20 | 2014-10-08 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
EP2716657A3 (en) * | 2006-12-20 | 2014-10-08 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
US8945550B2 (en) | 2006-12-20 | 2015-02-03 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
JP2010513539A (ja) * | 2006-12-20 | 2010-04-30 | エムエムアール インフォメーション システムズ,インコーポレーテッド | 抗体とその製造法および使用法 |
US20100150918A1 (en) * | 2007-04-03 | 2010-06-17 | Micromet Ag | Cross-species-specific binding domain |
US9101609B2 (en) | 2008-04-11 | 2015-08-11 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
JP2018064565A (ja) * | 2008-10-01 | 2018-04-26 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | PSCA×CD3、CD19×CD3、C−MET×CD3、エンドシアリン×CD3、EpCAM×CD3、IGF−1R×CD3、またはFAPアルファ×CD3の異種間特異的二重特異性単鎖抗体 |
KR20180026581A (ko) * | 2008-10-01 | 2018-03-12 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 PSCAxCD3, CD19xCD3, c-METxCD3, 엔도시알린xCD3, EpCAMxCD3, IGF-1RxCD3 또는 FAPαxCD3 이중특이적 단일쇄 항체 |
JP2016007217A (ja) * | 2008-10-01 | 2016-01-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | PSCA×CD3、CD19×CD3、C−MET×CD3、エンドシアリン×CD3、EpCAM×CD3、IGF−1R×CD3、またはFAPアルファ×CD3の異種間特異的二重特異性単鎖抗体 |
KR101837053B1 (ko) * | 2008-10-01 | 2018-03-12 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 PSCAxCD3, CD19xCD3, c-METxCD3, 엔도시알린xCD3, EpCAMxCD3, IGF-1RxCD3 또는 FAPαxCD3 이중특이적 단일쇄 항체 |
KR101942694B1 (ko) * | 2008-10-01 | 2019-01-25 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 PSCAxCD3, CD19xCD3, c-METxCD3, 엔도시알린xCD3, EpCAMxCD3, IGF-1RxCD3 또는 FAPαxCD3 이중특이적 단일쇄 항체 |
EP2370467B1 (en) | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
EP2352763B1 (en) | 2008-10-01 | 2016-04-13 | Amgen Research (Munich) GmbH | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
EP2356153B1 (en) | 2008-10-01 | 2016-05-04 | Amgen Research (Munich) GmbH | Cross-species-specific psmaxcd3 bispecific single chain antibody |
EP2352763B2 (en) † | 2008-10-01 | 2022-09-21 | Amgen Research (Munich) GmbH | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
JP2012504402A (ja) * | 2008-10-01 | 2012-02-23 | マイクロメット アーゲー | PSCA×CD3、CD19×CD3、C−MET×CD3、エンドシアリン×CD3、EpCAM×CD3、IGF−1R×CD3、またはFAPアルファ×CD3の異種間特異的二重特異性単鎖抗体 |
US11597766B2 (en) | 2008-11-07 | 2023-03-07 | Amgen Research (Munich) Gmbh | Treatment of acute lymphoblastic leukemia |
US20110262440A1 (en) * | 2008-11-07 | 2011-10-27 | Micromet Ag | Treatment of pediatric acute lymphoblastic leukemia |
US20130323247A1 (en) * | 2008-11-07 | 2013-12-05 | Micromet Ag | Treatment of acute lymphoblastic leukemia |
WO2011033105A1 (en) | 2009-09-18 | 2011-03-24 | Micromet Ag | Dosage regimen for administering an epcamxcd3 bispecific antibody |
AU2011320314B2 (en) * | 2010-10-29 | 2015-08-06 | Immunogen, Inc. | Novel EGFR-binding molecules and immunoconjugates thereof |
US10239952B2 (en) | 2011-04-01 | 2019-03-26 | Memorial Sloan Kettering Cancer Center | Anti-WT1/HLA bi-specific antibody |
US9782478B1 (en) | 2011-04-22 | 2017-10-10 | Aptevo Research And Development Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
EP2780374B1 (en) | 2011-11-15 | 2019-08-21 | Amgen Research (Munich) GmbH | Binding molecules for bcma and cd3 |
EP2780375B1 (en) | 2011-11-15 | 2019-09-11 | Amgen Research (Munich) GmbH | Binding molecules for bcma and cd3 |
WO2013083809A1 (en) | 2011-12-09 | 2013-06-13 | Amgen Research (Munich) Gmbh | Prevention of adverse effects caused by epcamxcd3 bispecific antibodies |
WO2013128027A1 (en) | 2012-03-01 | 2013-09-06 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
US20150231241A1 (en) * | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US10111954B2 (en) | 2012-08-14 | 2018-10-30 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US20160176968A1 (en) * | 2012-08-14 | 2016-06-23 | Ibc Pharmaceuticals, Inc. | T-Cell Redirecting Bispecific Antibodies for Treatment of Disease |
US10239938B2 (en) | 2012-08-14 | 2019-03-26 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
US20170022274A1 (en) * | 2012-08-14 | 2017-01-26 | Ibc Pharmaceuticals, Inc. | T-Cell Redirecting Bispecific Antibodies for Treatment of Disease |
US10183992B2 (en) | 2012-08-14 | 2019-01-22 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
US10245321B2 (en) | 2012-08-14 | 2019-04-02 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US10308688B2 (en) | 2012-08-14 | 2019-06-04 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
US20140099254A1 (en) * | 2012-08-14 | 2014-04-10 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US20160176980A1 (en) * | 2012-08-14 | 2016-06-23 | Ibc Pharmaceuticals, Inc. | T-Cell Redirecting Bispecific Antibodies for Treatment of Disease |
US11072656B2 (en) | 2012-09-21 | 2021-07-27 | Regeneran Pharmaceuticals, Inc. | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof |
AU2013318059B2 (en) * | 2012-09-21 | 2018-10-18 | Regeneron Pharmaceuticals, Inc. | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof |
AU2020239677B2 (en) * | 2012-09-21 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 And CD20, And Uses Thereof |
WO2014047231A1 (en) * | 2012-09-21 | 2014-03-27 | Regeneron Pharmaceuticals, Inc. | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
AU2013318059C1 (en) * | 2012-09-21 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof |
US11155621B2 (en) | 2012-09-21 | 2021-10-26 | Regeneran Pharmaceuticals, Inc. | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof |
EP4309740A3 (en) * | 2012-09-21 | 2024-06-05 | Regeneron Pharmaceuticals, Inc. | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
AU2018232926B2 (en) * | 2012-09-21 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof |
EP3778641A1 (en) * | 2012-09-21 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
EA033400B1 (ru) * | 2012-09-21 | 2019-10-31 | Regeneron Pharma | Антитело против cd3 и его применение |
US9657102B2 (en) | 2012-09-21 | 2017-05-23 | Regeneron Pharmaceuticals, Inc. | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof |
US10093736B2 (en) | 2012-11-13 | 2018-10-09 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
EP3447072A3 (en) * | 2013-03-05 | 2019-05-22 | Baylor College of Medicine | Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy |
US11173186B2 (en) | 2013-06-14 | 2021-11-16 | Psioxus Therapeutics Limited | Dosing regime and formulations for type B adenovirus |
US11161906B2 (en) | 2013-07-25 | 2021-11-02 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
US11439678B2 (en) | 2013-10-25 | 2022-09-13 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
US11938159B2 (en) | 2013-10-25 | 2024-03-26 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
WO2015070061A1 (en) * | 2013-11-07 | 2015-05-14 | Memorial Sloan-Kettering Cancer Center | Anti-wt1/hla bi-specific antibody |
US11001621B1 (en) | 2014-02-07 | 2021-05-11 | Mcmaster University | Trifunctional T cell-antigen coupler and methods and uses thereof |
US11008376B2 (en) | 2014-02-07 | 2021-05-18 | Mcmaster University | Trifunctional T cell-antigen coupler and methods and uses thereof |
US10435453B2 (en) | 2014-02-07 | 2019-10-08 | Mcmaster University | Trifunctional T cell-antigen coupler and methods and uses thereof |
US11421014B2 (en) | 2014-02-07 | 2022-08-23 | Mcmaster University | Trifunctional T cell-antigen coupler and methods and uses thereof |
US11434300B2 (en) | 2014-03-19 | 2022-09-06 | Regeneron Pharmaceuticals, Inc. | Methods and antibody compositions for tumor treatment |
US10550193B2 (en) | 2014-03-19 | 2020-02-04 | Regeneron Pharmaceuticals, Inc. | Methods and antibody compositions for tumor treatment |
US10669337B2 (en) | 2014-07-25 | 2020-06-02 | Cytomx Therapeutics, Inc. | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same |
US11802158B2 (en) | 2014-07-25 | 2023-10-31 | Cytomx Therapeutics, Inc. | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same |
US11661462B2 (en) | 2014-07-31 | 2023-05-30 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody contructs |
WO2016016859A1 (en) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs |
US10662244B2 (en) | 2014-11-17 | 2020-05-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3XCD20 bispecific antibody |
US20170362299A1 (en) * | 2014-12-08 | 2017-12-21 | 1Globe Biomedical Co., Ltd. | Soluble Universal ADCC-Enhancing Synthetic Fusion Gene and Peptide Technology and Its Use Thereof |
US11028171B2 (en) | 2015-04-17 | 2021-06-08 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs for CDH3 and CD3 |
EP4276116A2 (en) | 2015-04-17 | 2023-11-15 | Amgen Research (Munich) GmbH | Bispecific antibody constructs for cdh3 and cd3 |
US11926666B2 (en) | 2015-04-17 | 2024-03-12 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs for CDH3 and CD3 |
WO2016166360A1 (en) | 2015-04-17 | 2016-10-20 | Bayer Pharma Aktiengesellschaft | Bispecific antibody constructs for cdh3 and cd3 |
US12084518B2 (en) | 2015-05-21 | 2024-09-10 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
WO2017021354A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Antibody constructs for cd70 and cd3 |
EP3912999A1 (en) | 2015-07-31 | 2021-11-24 | Amgen Research (Munich) GmbH | Bispecific antibody constructs binding egfrviii and cd3 |
US11591396B2 (en) | 2015-07-31 | 2023-02-28 | Amgen Research (Munich) Gmbh | Antibody constructs for DLL3 and CD3 |
WO2017021370A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs binding egfrviii and cd3 |
EP4219562A2 (en) | 2015-07-31 | 2023-08-02 | Amgen Research (Munich) GmbH | Antibody constructs for flt3 and cd3 |
EP4382169A2 (en) | 2015-07-31 | 2024-06-12 | Amgen Research (Munich) GmbH | Antibody constructs for dll3 and cd3 |
US11447567B2 (en) | 2015-07-31 | 2022-09-20 | Amgen Research (Munich) Gmbh | Antibody constructs for FLT3 and CD3 |
WO2017021349A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs binding dll3 and cd3 |
WO2017021362A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Antibody constructs for flt3 and cd3 |
US10683351B2 (en) | 2015-07-31 | 2020-06-16 | Amgen Research (Munich) Gmbh | Antibody constructs for DLL3 and CD3 |
WO2017021356A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs binding mesothelin and cd3 |
EP3865514A1 (en) | 2015-07-31 | 2021-08-18 | Amgen Research (Munich) GmbH | Bispecific antibody constructs binding dll3 and cd3 |
US10294300B2 (en) | 2015-07-31 | 2019-05-21 | Amgen Research (Munich) Gmbh | Antibody constructs for DLL3 and CD3 |
US11884720B2 (en) | 2015-07-31 | 2024-01-30 | Amgen Research (Munich) Gmbh | Antibody constructs for MSLN and CD3 |
US10851170B2 (en) | 2015-07-31 | 2020-12-01 | Amgen Research (Munich) Gmbh | Antibody constructs for CD70 and CD3 |
EP4327885A2 (en) | 2015-07-31 | 2024-02-28 | Amgen Research (Munich) GmbH | Antibody constructs for msln and cd3 |
US10519241B2 (en) | 2015-07-31 | 2019-12-31 | Amgen Research (Munich) Gmbh | Antibody constructs for EGFRVIII and CD3 |
US11155629B2 (en) | 2015-07-31 | 2021-10-26 | Amgen Research (Munich) Gmbh | Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3 |
WO2017021526A1 (en) | 2015-08-05 | 2017-02-09 | Amgen Research (Munich) Gmbh | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
US11155622B2 (en) | 2015-12-17 | 2021-10-26 | Psioxus Therapeutics Limited | Virus encoding an anti-TCR-complex antibody or fragment |
US11419933B2 (en) | 2016-01-25 | 2022-08-23 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs |
US11434302B2 (en) | 2016-02-03 | 2022-09-06 | Amgen Research (Munich) Gmbh | Bispecific T cell engaging antibody constructs |
US10781264B2 (en) | 2016-02-03 | 2020-09-22 | Amgen Research (Munich) Gmbh | PSMA and CD3 bispecific T cell engaging antibody constructs |
US11352433B2 (en) | 2016-02-03 | 2022-06-07 | Amgen Research (Munich) Gmbh | BCMA and CD3 bispecific T cell engaging antibody constructs |
EP4039709A1 (en) | 2016-02-03 | 2022-08-10 | Amgen Research (Munich) GmbH | Bcma and cd3 bispecific t cell engaging antibody constructs |
US10301391B2 (en) | 2016-02-03 | 2019-05-28 | Amgen Research (Munich) Gmbh | BCMA and CD3 bispecific T cell engaging antibody constructs |
EP4206228A1 (en) | 2016-02-03 | 2023-07-05 | Amgen Research (Munich) GmbH | Psma and cd3 bispecific t cell engaging constructs |
WO2017182427A1 (en) | 2016-04-19 | 2017-10-26 | Amgen Research (Munich) Gmbh | Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia |
US11053318B2 (en) | 2016-04-19 | 2021-07-06 | Amgen Research (Munich) Gmbh | Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
US11613572B2 (en) | 2016-06-21 | 2023-03-28 | Teneobio, Inc. | CD3 binding antibodies |
EP4273252A2 (en) | 2016-08-29 | 2023-11-08 | Akamis Bio Limited | Adenovirus armed with bispecific t cell engager (bite) |
EP4273252A3 (en) * | 2016-08-29 | 2024-04-17 | Akamis Bio Limited | Adenovirus armed with bispecific t cell engager (bite) |
US11505606B2 (en) | 2016-09-14 | 2022-11-22 | Teneobio, Inc. | CD3 binding antibodies |
US11434299B2 (en) | 2016-12-21 | 2022-09-06 | Teneobio, Inc. | Anti-BCMA heavy chain-only antibodies |
WO2018141910A1 (en) | 2017-02-02 | 2018-08-09 | Amgen Research (Munich) Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
WO2018204907A1 (en) | 2017-05-05 | 2018-11-08 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
US11918650B2 (en) | 2017-05-05 | 2024-03-05 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
WO2018219901A1 (en) | 2017-06-01 | 2018-12-06 | F. Hoffmann-La Roche Ag | Treatment method |
EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
WO2018220099A1 (en) | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
US11970540B2 (en) | 2017-06-20 | 2024-04-30 | Teneobio, Inc. | Anti-BCMA heavy chain-only antibodies |
US11306142B2 (en) | 2017-07-05 | 2022-04-19 | Ucl Business Ltd | Bispecific antibodies to ROR1 and CD3 |
US11466083B2 (en) | 2017-07-05 | 2022-10-11 | Ucl Business Ltd | ROR1 antibodies |
US11723925B2 (en) | 2017-07-05 | 2023-08-15 | Ucl Business Ltd | ROR1 CAR T-cells |
US11541103B2 (en) | 2017-08-03 | 2023-01-03 | Amgen Inc. | Interleukin-21 mutein/ anti-PD-1 antibody conjugates |
WO2019043020A1 (en) | 2017-08-28 | 2019-03-07 | Psioxus Therapeutics Limited | ADENOVIRUS EQUIPPED WITH A BISPECIFIC T CELL ACTIVATOR (BITE) |
US11840702B2 (en) | 2017-08-28 | 2023-12-12 | Akamis Bio Limited | Adenovirus armed with bispecific T cell activator |
EP4403227A2 (en) | 2017-08-28 | 2024-07-24 | Akamis Bio Limited | Adenovirus armed with bispecific t cell engager (bite) |
US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
US11744892B2 (en) | 2017-09-08 | 2023-09-05 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
US11744893B2 (en) | 2017-09-08 | 2023-09-05 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
US11198737B2 (en) | 2017-10-12 | 2021-12-14 | Mcmaster University | T cell-antigen coupler with Y177 mutation and methods of uses thereof |
US11643472B2 (en) | 2017-10-12 | 2023-05-09 | Mcmaster University | T cell-antigen coupler with Y182T mutation and methods and uses thereof |
US11970545B2 (en) | 2017-10-12 | 2024-04-30 | Mcmaster University | T cell-antigen coupler with Y182T mutation and methods of uses thereof |
US11976125B2 (en) | 2017-10-13 | 2024-05-07 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
WO2019118426A1 (en) | 2017-12-11 | 2019-06-20 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
WO2019133961A1 (en) | 2017-12-29 | 2019-07-04 | Amgen Inc. | Bispecific antibody construct directed to muc17 and cd3 |
US11518808B2 (en) | 2018-01-12 | 2022-12-06 | Amgen Inc. | Anti-PD-1 antibodies and methods of treatment |
WO2019140196A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Anti-pd-1 antibodies and methods of treatment |
US11998580B2 (en) | 2018-01-31 | 2024-06-04 | Akamis Bio Limited | Group B adenovirus-containing formulation |
US11492409B2 (en) | 2018-06-01 | 2022-11-08 | Novartis Ag | Binding molecules against BCMA and uses thereof |
US20220002398A1 (en) * | 2018-06-07 | 2022-01-06 | Oncoone Research & Development Gmbh | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT |
US11530274B2 (en) | 2018-07-02 | 2022-12-20 | Amgen Inc. | Anti-STEAP1 antigen-binding protein |
US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
US11111298B2 (en) | 2018-07-17 | 2021-09-07 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
US11406667B2 (en) | 2018-07-17 | 2022-08-09 | Triumvira Immunologies USA, Inc. | T cell-antigen coupler with various construct optimizations |
US11878035B2 (en) | 2018-07-17 | 2024-01-23 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
US11976117B2 (en) | 2018-07-17 | 2024-05-07 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
WO2020025532A1 (en) | 2018-07-30 | 2020-02-06 | Amgen Research (Munich) Gmbh | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3 |
WO2020025596A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Research (Munich) Gmbh | Dosing regimen for bcma-cd3 bispecific antibodies |
US11692031B2 (en) | 2018-08-03 | 2023-07-04 | Amgen Research (Munich) Gmbh | Antibody constructs for CLDN18.2 and CD3 |
WO2020025792A1 (en) | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
US11590223B2 (en) | 2018-08-31 | 2023-02-28 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies |
CN110872356A (zh) * | 2018-09-03 | 2020-03-10 | 广西慧宝源健康产业有限公司 | 双特异性抗体及其使用方法 |
CN110872356B (zh) * | 2018-09-03 | 2023-06-13 | 广西慧宝源健康产业有限公司 | 双特异性抗体及其使用方法 |
US11807692B2 (en) | 2018-09-25 | 2023-11-07 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
US11505614B2 (en) | 2018-09-28 | 2022-11-22 | Amgen Inc. | Antibodies binding to soluble BCMA |
WO2020069303A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Antibodies against soluble bcma |
WO2020077212A1 (en) | 2018-10-11 | 2020-04-16 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
US11945869B2 (en) | 2018-10-11 | 2024-04-02 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
US11208485B2 (en) | 2018-10-11 | 2021-12-28 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
WO2020076992A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
WO2020076977A2 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
WO2020076970A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
WO2020086635A1 (en) | 2018-10-23 | 2020-04-30 | Amgen Inc. | Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions |
EP3891181A4 (en) * | 2018-12-04 | 2022-08-17 | Novartis AG | BINDING MOLECULES AGAINST CD3 AND USES THEREOF |
WO2020159838A1 (en) | 2019-01-28 | 2020-08-06 | Amgen Inc. | A continuous manufacturing process for biologics manufacturing by integration of drug substance and drug product processes |
EP3969479A4 (en) * | 2019-05-14 | 2023-02-08 | Harpoon Therapeutics, Inc. | EPCAM-BINDING PROTEINS AND METHODS OF USE |
WO2020247852A1 (en) | 2019-06-07 | 2020-12-10 | Amgen Inc. | Bispecific binding constructs |
WO2020247854A1 (en) | 2019-06-07 | 2020-12-10 | Amgen Inc. | Bispecific binding constructs with selectively cleavable linkers |
WO2020252442A1 (en) | 2019-06-13 | 2020-12-17 | Amgen Inc. | Automated biomass-based perfusion control in the manufacturing of biologics |
US11905326B2 (en) | 2019-06-14 | 2024-02-20 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to CD22 and CD3 |
WO2021041300A3 (en) * | 2019-08-23 | 2021-04-01 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
WO2021050640A1 (en) | 2019-09-10 | 2021-03-18 | Amgen Inc. | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity |
WO2021091906A1 (en) | 2019-11-04 | 2021-05-14 | Amgen Inc. | Methods for treating leukemia |
EP3819312A1 (en) | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
EP3819007A1 (en) | 2019-11-11 | 2021-05-12 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
EP4424709A2 (en) | 2019-11-11 | 2024-09-04 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
WO2021094000A1 (en) | 2019-11-11 | 2021-05-20 | Amgen Research (Munich) Gmbh | Dosing regimen for anti-bcma agents |
WO2021097344A1 (en) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
WO2021127528A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
WO2021146336A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
WO2021146328A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Formulations for protein therapeutics |
WO2021150824A1 (en) | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
WO2021158469A1 (en) | 2020-02-03 | 2021-08-12 | Amgen Inc. | Multivariate bracketing approach for sterile filter validation |
WO2021183861A1 (en) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
WO2021188851A1 (en) | 2020-03-19 | 2021-09-23 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
US11390681B2 (en) | 2020-04-29 | 2022-07-19 | TeneoTwo, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
WO2021236638A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
WO2021243320A2 (en) | 2020-05-29 | 2021-12-02 | Amgen Inc. | Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3 |
WO2021247812A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Bispecific binding constructs |
WO2022056267A1 (en) | 2020-09-11 | 2022-03-17 | Amgen Inc. | Materials and methods to reduce protein aggregation |
WO2022060901A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
WO2022060878A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for treating prostate cancer |
WO2022097068A1 (en) | 2020-11-05 | 2022-05-12 | Dcprime B.V. | Use of tumor-independent antigens in immunotherapies |
WO2022096716A2 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Multitargeting bispecific antigen-binding molecules of increased selectivity |
WO2022096698A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Polypeptide constructs binding to cd3 |
WO2022096704A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
WO2022096700A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Research (Munich) Gmbh | Polypeptide constructs selectively binding to cldn6 and cd3 |
WO2022103781A1 (en) | 2020-11-10 | 2022-05-19 | Amgen Inc. | Methods for administering a bcma x cd3 binding molecule |
US11617767B2 (en) | 2020-11-20 | 2023-04-04 | Simcere Innovation, Inc. | Armed dual CAR-T compositions and methods for cancer immunotherapy |
WO2022120033A1 (en) | 2020-12-03 | 2022-06-09 | Amgen Inc. | Immunoglobuline constructs with multiple binding domains |
WO2022192504A1 (en) | 2021-03-10 | 2022-09-15 | Amgen Inc. | Methods for purification of recombinant proteins |
WO2022191971A1 (en) | 2021-03-10 | 2022-09-15 | Amgen Inc. | Parallel chromatography systems and methods |
WO2022212831A1 (en) | 2021-04-02 | 2022-10-06 | Amgen Inc. | Mageb2 binding constructs |
WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
WO2022228706A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
WO2022234102A1 (en) | 2021-05-06 | 2022-11-10 | Amgen Research (Munich) Gmbh | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
WO2022243347A1 (en) | 2021-05-18 | 2022-11-24 | Christian-Albrechts-Universität Zu Kiel | Co-stimulatory multispecific antibodies |
WO2022246244A1 (en) | 2021-05-21 | 2022-11-24 | Aptevo Research And Development Llc | Dosing regimens for protein therapeutics |
US12016923B2 (en) | 2021-06-01 | 2024-06-25 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 T cell-antigen couplers and uses thereof |
US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
WO2023076318A1 (en) | 2021-10-27 | 2023-05-04 | Amgen Inc. | Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy |
WO2023079493A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
WO2023078968A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
WO2023110918A1 (en) | 2021-12-14 | 2023-06-22 | Cdr-Life Ag | Dual mhc-targeting t cell engager |
WO2023164474A1 (en) | 2022-02-23 | 2023-08-31 | Amgen Inc. | Cancer treatment targeting dll3 |
WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
WO2023218027A1 (en) | 2022-05-12 | 2023-11-16 | Amgen Research (Munich) Gmbh | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
WO2024056758A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
WO2024187062A1 (en) | 2023-03-08 | 2024-09-12 | Amgen Inc. | Controlled-ice nucleation lyophilization process for bispecific molecules |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8076459B2 (en) | Multispecfic deimmunized CD3-binders | |
EP1716178B1 (en) | Less immunogenic binding molecules | |
US8790645B2 (en) | Pharmaceutical composition comprising a bispecific antibody for EpCAM | |
ZA200508279B (en) | Pharmaceutical composition comprising a bispecific antibody for epcam |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480030150.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006/01699 Country of ref document: ZA Ref document number: 200601699 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004283850 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 546173 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2004283850 Country of ref document: AU Date of ref document: 20041015 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004790488 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004283850 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/004035 Country of ref document: MX Ref document number: 174902 Country of ref document: IL Ref document number: 2542239 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1280/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006534709 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067009529 Country of ref document: KR Ref document number: 2006116459 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004790488 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067009529 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10572740 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0415457 Country of ref document: BR |